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Chapter 1 - Introduction
1.1 Background
In the practice of evidence based medicine, randomised controlled trials (RCTs)
provide the best evidence for evaluating treatment effects. One of the major
challenges to the conduct of randomised controlled trials is the recruitment of
adequate numbers of participants.  In trials involving children, the problem of
recruitment is more pronounced, with many paediatric trials having only small
numbers of participants. Although recruiting children is often difficult, little is known
about this important subject to help researchers working with children.
1.2 Aims
The aims of this thesis are to explore and analyse factors that impact on the
recruitment of children to randomised controlled trials and to identify elements that
can be modified to improve children’s participation in trials in the future. This will be
achieved by:
· summarising the literature on the effectiveness of different methods of
recruiting study participants to RCTs;
· exploring and analysing attitudes of paediatricians to RCTs involving
children;
· analysing and comparing paediatricians’ and adult physicians’ treatment
philosophies and attitudes to RCTs participation;
· exploring and analysing attitudes of parents to RCTs involving children.
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1.3 Overview of chapters
This thesis contains both qualitative and quantitative research, and explores issues
surrounding the recruitment of children to RCTs. Research into research methodology
is a relatively new area of enquiry, with previous work mostly confined to research
methodology used in adult research. Although much has been learned about the
recruitment of adults to trials, little is known about factors influencing decisions for trial
participation for children. Chapter 2 contains a review of the literature on research
regarding children’s participation in randomised controlled trials in the context of
research on adult recruitment to trials and barriers to trial participation.
How do researchers recruit participants to RCTs? Although many different
recruitment strategies have been used to facilitate the recruitment of study
participants for RCTs, the relative effectiveness of each has not been assessed. The
systematic review described in Chapter 3 systematically reviews and summarises the
literature on the effectiveness of different methods of recruiting study participants to
RCTs and identifies effective and ineffective strategies. Because of the small number
of RCTs available on this subject, the systematic review was expanded to also
include observational studies.
As doctor-related factors have been identified in the adult literature as one of the main
causes of poor trial recruitment, it is important to explore paediatricians’ attitudes to
RCTs involving children, and identify possible barriers to trial participation. It is
hypothesised that paediatricians are more hesitant about children’s participation in
RCTs (compared with adult physicians), and that doctors’ previous research
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experience may have a positive influence on attitudes to trial participation. This thesis
examines paediatricians’ attitudes to children’s participation in trials by qualitative
analysis of focus group discussions (Chapter 4). It also quantitatively compares
questionnaire responses between paediatricians and adult physicians on their
treatment philosophies and attitudes to RCT participation (Chapter 5).
It is equally important to explore and analyse parents’ attitudes to children’s trial
participation, and attempt to understand how parents make this decision. It is
hypothesised that parents’ decision making processes are influenced by their
perception of risks and benefits for trial participation, their doctors’ advice, their child’s
illness severity and their attitudes toward research and their child’s involvement. This
thesis explores parents’ attitudes to children’s participation in randomised controlled
trial by qualitative analysis of focus group discussions and identifies important factors
in parents’ decision making process for trial participation (Chapter 6).
1.4 Conclusion
Evaluating therapies by RCTs involving children is essential for their health and well-
being. The success of RCTs involving children depends on effective recruitment. This
thesis is the only extensive work which addresses this issue, and plays a key role in
understanding paediatricians’ and parents’ attitudes to children’s participation in trials.
The systematic review of literature on the effectiveness of recruitment strategies for
RCTs is much needed for both adult and paediatric trials. Future research in the
development of ethical and appropriate recruitment strategies for paediatric trials is
needed to ensure that trials for children can be completed in a cost effective and
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timely manner thus improving evaluation of therapies and minimising unanticipated
adverse effects for children.
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Chapter 2 - Literature Review
2.1 Randomised controlled trials
2.1.1 The role of randomised controlled trials
The last decade has seen the growth of the “Evidence Based Medicine” movement
which is founded upon the ideal that decisions for patient care should involve the
“conscientious, explicit and judicious use of current best evidence” (3). Randomised
controlled trials (RCTs) and systematic reviews of RCTs provide the highest level of
evidence for intervention questions and have become the “gold standard” by which
the treatment recommendations are judged (1;2;4). Traditionally, decisions for patient
care were based on personal experience, anecdotal case histories or non-random
comparisons of groups of patients, which were subject to many biases. The
randomised trial, allegedly first introduced in 1947 (5), provided a study design that
resulted in a much more reliable estimate of the relative effects of different
interventions. It has the potential to prevent the propagation of worthless treatments
and confirm the value of effective treatments. It also allows identification of moderate
benefits that would otherwise be obscured by bias and random effect (6). For
example, the benefits of RCTs are clearly demonstrated by the improved five-year
survival for childhood acute lymphoblastic leukaemia from 25% to over 70% as a
result of evaluating therapies by multicentre trials (7).
2.1.2 Ethics of randomised controlled trials
The Nuremberg Code formulated in 1947 as a response to the inhumane
experimentation conducted in Nazi camps (8) and the Declaration of Helsinki in 1964
(9) form the basis of ethical guidelines for involving human subjects in research.
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There is a general ethical principle that the potential benefit of research (to the
participant and to society as a whole) should outweigh the potential risks involved.
The fundamental ethical issue surrounding clinical trials reflects a conflict between the
need to safeguard individual patients versus the obligation to society to facilitate
research which will result in improved outcomes for all in the future.
The ethical grounds for conducting RCTs arise from clinical equipoise, a state of
collective uncertainty within the expert medical community about the relative merits of
alternative treatments (10). For example, when there is a promising but unproven new
treatment that may offer advantages over the standard treatment, or when there is a
split in opinion within the clinical community about best treatment, a RCT is justified. It
is argued that RCTs are justified if the following criteria are met (11):
· true clinical equipoise is present;
· the trial is designed as a crucial experiment between therapeutic alternatives;
· an institutional review board has reviewed and approved the protocol;
· it is certified that no physician has a conflict of interest or incentive that would
threaten the physician-patient relationship;
· comprehensive informed consent has been obtained;
· placebos are not used if an effective treatment exists;
· a data monitoring committee will either end the trial when clinical equipoise is
displaced by statistically significant data or will supply doctors and patients with
significant safety and therapeutic information relevant to a reasonable person’s
decision to remain in or withdraw from the trial;
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· the physicians have the right to recommend withdrawal and the patients have the
right to withdraw at any time.
The public perception of clinical trials as experimentation involving patients being
used as guinea pigs has led to a pronounced distinction being made between clinical
practice and clinical research. It is often seen as more acceptable to use an untested
medication on patients than to enrol them in a RCT where the effects of interventions
can be monitored and pooled to provide information. A double standard exists
whereby a treatment given outside a clinical trial is less stringently reviewed than a
protocol treatment. Some have argued that where clinical equipoise exists, it is
unethical not to recommend trial entry to eligible patients, because the doctor is
implying he or she knows the best treatment despite the agreed lack of scientific proof
(12).
2.1.3 Randomised controlled trials involving children
There is general agreement that involvement of children in trials is not merely
desirable but necessary for the promotion of their health and well being (13).
Clinicians are often faced with a lack of evidence when making treatment decisions
because of a paucity of RCTs involving children. Too often, clinical decisions about
the care of children are based on research conducted in adults or even no research at
all (14). Indeed, many medications given to children are off label (prescribed for
children despite being approved only for adults), unlicensed (not licensed for use in
children), and often without adequate pharmacokinetic or safety data for children (15-
19). For example, only 5 of the 80 drugs most frequently prescribed for children in the
US have Food and Drug Administration (FDA) approval for children. It is argued that
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extrapolation from adult studies is inappropriate because children are different from
adults and their disease processes, drug metabolism and effects of intervention often
differ (18). Treatments that are effective and safe in adults are not necessarily so in
children. For example, many drugs including aspirin, tetracycline, thalidomide and
chloramphenicol, which are safe for adults have specific adverse effects in children.
Extrapolation from adult studies and treating children with untested drugs is therefore
fraught with danger.
Voluntary informed consent by research participants is a fundamental prerequisite to
the conduct of all health research, and the cornerstone of the Nuremberg Code (8). In
research involving children the issues of consent by proxy by the child’s parents or
guardians and the age when children can competently give legally effective consent
are controversial and hotly debated (13). Many guidelines stipulate that the child’s
assent should also be sought if they are old enough to comprehend their participation
in research (20). The National Commission for Protection of Human Subjects of
Biomedical and Behavioral Research established age 7 as a reasonable minimum
age for involving children in the assent process (20).
More recent guidelines have also added a number of other conditions specifically
designed to protect children. These include that children may participate only if the
research cannot equally well be done on adults and the purpose of the research is to
obtain knowledge relevant to the health needs of children. Some guidelines also
recommend that older children be used before younger children, that the research be
designed and carried out by people experienced in doing research with children and
limiting the number of participants to what is scientifically and clinically essential (13).
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2.1.4 Legislation for inclusion of children in trials
There has recently been a shift in the scientific community’s attitudes, as the
importance of clinical trials in children is increasingly recognised (21). Some view the
trialling of drugs on adults before offering trials to children as depriving children of
potentially useful therapy (22). Many government and research bodies are developing
guidelines for the inclusion of children in research (23-30). The United States of
America (US) has led the world in instituting legislative changes to address this issue.
The FDA’s Pediatric Rule of 1998 requires that new therapies or new indications for
existing therapies that will be used by children have to be studied in children.
Unfortunately, this regulation was suspended by court action in the US District Court
for Columbia on October 17, 2002 (31) after being contested by several groups
including the Competitive Enterprise Institute and the Association of American
Physicians and Surgeons (32). However, the US Secretary of Health and Human
Services and the FDA Commissioner are currently urging the US congress to codify
the regulation and make it law, which would make the court action moot. The FDA
Modernization Act (FDAMA)’s Pediatric Exclusivity Provision (1997- Dec 2001) (23)
also provided incentives for industries to conduct paediatric studies by offering an
additional six-month market exclusivity to existing patents or exclusivity period for all
products that have been trialled in children. This exclusivity was reauthorised in the
Best Pharmaceuticals for Children Act (Jan 2002). However, there is no legislation
regarding paediatric licensing in Australia and Europe.
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2.2 Participation in randomised controlled trials
2.2.1 Benefits
Participants of RCTs often derive many benefits from trial participation, including
having an opportunity to access new treatments which may not be routinely available.
The treatment offered to the control group represents the current best standard
treatment while those allocated to the experimental group receive a treatment
hypothesised to be as good or better than standard treatments. It can therefore be
argued that well designed RCTs offer patients the optimum treatment approach
(12;33). There may also be benefits for patients who receive treatment at a hospital or
institution involved in RCTs, as doctors who participate in clinical trials are more likely
to incorporate trial findings and published data into clinical practice (34).
There is an emerging body of literature demonstrating inclusion benefits for all trial
participants (35). The improved outcomes of trial participants have also been noted in
RCTs involving children (36). Participants of RCTs, including those assigned to a
placebo arm, are found to have similar or improved outcomes compared with eligible
non-participants. Participants have lower mortality, fewer clinical events and lower
complication rates when compared with similar patients treated outside trials. This
“survival advantage” is not explained by differences in pre-treatment disease status or
factors of known prognostic significance (37). The improved outcomes may reflect
volunteer bias, but may also be partly due to closer monitoring and better care of trial
participants.
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2.2.2 Risks
What constitutes acceptable risks for children participating in research is currently
under debate. Most guidelines on research involving children draw a distinction
between therapeutic research (which is intended to be of direct benefit to the
participant), and non-therapeutic research (which is intended to produce knowledge
of general importance with no direct benefit the participant). Higher degrees of
ethically permissible risk are allowed in therapeutic research than non-therapeutic
research involving children (13). Other potential risks of trial participation for children
such as psychological trauma are increasingly being recognised and assessed
(38;39).
2.2.3 Recruitment to trials
Recruitment is fundamental to RCTs, as the power of the study to detect a statistically
significant treatment effect is directly related to the size of the trial. However, despite
the rigorous scrutiny by ethics committees to ensure that RCTs are safe and ethical,
and despite the benefits to participants and society, the majority of eligible people do
not participate in RCTs (40-42). Participation rates are low in many trials (3%-20%),
recruitment generally takes longer than investigators initially anticipate, and costs of
recruitment can range from 4% to 16% of the total study budget (40;43). Problematic
recruitment is the most common cause of delays, increased costs and failure to
complete trials (44).
Most paediatric RCTs have only small numbers of participants (e.g. a review of trials
published in “Archives of Disease in Childhood” from 1982 to 1996 showed that half
of the trials had 40 or less participants in total) (14), and are therefore usually
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inadequately powered to detect small or moderate treatment effects which may be of
clinical significance (14;45). Although problems with recruitment are not new, the
study of issues surrounding recruitment to trials has only emerged in the last few
years.
Although much is known about reasons for poor recruitment to adult trials, little is
known about paediatric recruitment. The reasons for low accrual rates for adults
participants are multifactorial. There are factors relating to the doctor, the patient and
the trial itself that influence willingness to participate in trials. One large review article
identified 84 papers which reported findings relating to recruitment of clinicians or
patients to clinical trials (41). The following describes what is known about trial
participation for adults.
2.3 Research on barriers to trial participation in adults
2.3.1 Doctor factors
With the advent of RCTs, doctors often have to perform both the roles of scientists
and clinicians, roles that were previously quite separate. Taylor believes that doctors'
reluctance to participate in RCTs is a foreseeable consequence of the attempt to
integrate these conflicting roles (46).
Doctors’ reluctance to enrol patients is one of the most significant obstacles to trial
success (47-49) as patients will rarely participate in a RCT unless actively
recommended to do so by their physician (50;51). The major reason for
nonparticipation in RCTs by eligible patients is physician preference.  Extensive
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literature has been written about doctors’ barriers to trial participation (41;46;49;52-
57). Common physicians' barriers include forgetfulness or lack of awareness of trials
that are open for accrual (57;58), time (54;55;58-60) and financial constraints (61),
the extra work involved for physicians (51), lack of resources including data
management for trials (56), lack of rewards and recognition (46;53), difficulty with
ethics requirements and the informed consent procedures (51;55;62), problems with
complying with the protocol (55;56;60), concerns about the effect on the doctor-
patient relationship (55;60;62;63), discomfort with randomisation (40;64), preference
for a particular treatment (40;54;55;60), dislike of loss of autonomy (62) and open
discussion involving uncertainty (55), mistrust of researchers (57), fear of losing
patients (40;57), perceived conflict between the roles of caregiver and scientist
(46;55) and concerns about the patient (40) such as feeling personally responsible for
treatment failures (55).
2.3.2 Patient factors
The ultimate success of a RCT depends on patient participation. Many theories have
been postulated to explain the variations observed in clinical decision making
behaviour, including decisions for trial participation. The core issues include the
probability of an expected outcome, the patient’s (or parent’s) perception of the
severity of that outcome, the patient's (or parent’s) or physician’s idea of the probable
usefulness of participating in a trial in affecting that outcome and the perceived risks
or cost of trial participation (47).
Common reasons why patients participate in trials include recommendations by their
doctor (65), altruistic reasons (such as benefiting others and advancing medical
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knowledge) and to get the best care (66;67). There are many studies on patient
barriers to trial participation. Barriers identified include additional demands on patients
(such as extra procedures, time pressures, travel and extra costs) (66;68;69), patient
preference for a particular treatment (41;69;70), fears of uncertainty and being an
“experimental subject” (41;44;68), fear of being randomised to the less effective
treatment (71), issues of consent and information (65), and the influence of significant
others (41;71).
A number of demographic characteristics such as severity of illness, level of
education, age and sex are suggested to be associated with willingness to participate
in trials. However, the evidence is equivocal and conflicting in some instances
(40;41;72) .
2.3.3 Trial factors
Physicians or patients may be concerned about certain aspects of the trial itself,
which may impede participation. The trial question may be considered unimportant or
irrelevant. There may also be concerns about the trial design (that the protocol is too
complex or incompatible with normal clinical practice, the treatment being offered is
too toxic or the control arm is not considered standard therapy).
The rationale for random allocation of treatment and the use of placebo is generally
poorly understood (49;73). Many are discouraged from trial participation because of
the presence of a placebo arm (74). It is also more difficult to recruit for trials where
there is a large difference between treatment arms (e.g. between surgery and
radiotherapy).
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2.4 Research on barriers to trial participation in children
Recruitment issues in paediatric and adult RCTs are thought to be quite different (75).
Although there has been no published data, it is postulated that the recruitment of
children to RCTs is more difficult than the recruitment of adults (76) with the exception
of paediatric oncology trials (75;77). The contrast between recruitment for paediatric
and adult oncology trials is striking (75).  
Childhood cancer is comparatively rare and referral patterns to tertiary (usually
academic) centres are well-established.  Paediatric cancer centres have long been
organised into national and multi-national paediatric cancer cooperative groups which
enrol high proportions of incident paediatric cancer cases in the population into
clinical trials. Approximately 94% of children in the US younger than 15 years of age
who have been diagnosed with cancer are seen at a  multi-national paediatric cancer
cooperative group (78). Through such paediatric cancer trial groups, the power of
systematic clinical trials to improve outcomes has been amply demonstrated (79).
This, together with widespread participation in trials, has combined to create a culture
in which there is almost a fusion between clinical research and clinical practice in the
field of paediatric oncology.  The high participation rate in clinical trials of children with
cancer (75) stands in marked contrast to the mere 2-3% of adults with cancer who are
participating in trials (80). There are a variety of practical as well as philosophical
reasons for the low rates of accrual to adult oncology trials, such as more widely
dispersed and variable patterns of cancer care providers, as well as economic
pressures (81).
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2.4.1 Doctors’ barriers
Very little is known about the recruitment of children to RCTs as previous research on
recruitment of participants focuses on adult trials (55;64;72;82;82). Although much is
known about doctors’ barriers to trial participation for adults, little is known about
paediatricians’ attitudes to trials. There is one article about informed consent for trials
in children, which suggests that paediatricians find obtaining informed consent for
trials burdensome (83), and may preferentially approach certain parents (e.g. of
patients who are less severe in illness) for trial participation, hence affecting the
generalisability of the trial.
2.4.2 Children’s barriers
There has been only one study on children’s response to trial participation (84). This
study assessed why adolescent diabetic patients refused to participate in a RCT of
intensive therapy for diabetes. Cited reasons for nonparticipation include
inconvenience (increased visits and transport difficulties) and dislike of extra blood
tests and insulin injections.
2.4.3 Parents’ barriers
There are several studies on parental response to their child’s participation in trials,
comparing consenting parents with those who refused trial participation. Motivators
for trial participation that were identified include altruistic reasons and doctors’ advice,
and barriers to participation include inconvenience and safety concerns (65;85-88).
Zupancic found that parents are influenced by risk and benefit assessments, attitudes
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towards research and the integrity of the consent process when making consent
decisions on behalf of their infants (88). It is debatable whether parental
sociodemographic characteristics influence recruitment. Two studies identified
parental attributes influencing willingness to participate in trials (68;89;90). Harth and
Thong found that parents who volunteer their children for clinical trials were less
educated and were from lower socio-economic groups, had less social support,
consumed more habit-forming substances and displayed greater health-seeking
behaviour than parents who declined participation (68;90). In contrast, the study by
Zupancic found that sociodemographic characteristics did not significantly influence
recruitment (88).
Several studies found that parents have a poor understanding of trials and the
informed consent process (65;73;91).  There is one study on the readability of
paediatric biomedical research informed consent forms which suggests that the
readability factor may compromise the informed consent procedure (92).
2.5 Recruitment strategies for trials
The study of recruitment strategies is a relatively new area of inquiry, with much of
the work focusing on recruitment to non-randomised studies (such as to
questionnaires (93-95), cohort studies (96) and epidemiological studies (97)), to
screening programs (such as pap smear (98;99), mammography (100;101) and
osteoporosis screening (102)), and to health promotional activities (such as smoking
cessation(103-105), vaccination (106), blood donation (107;108) and alcohol (109),
nutritional (110) and exercise programs (111)).
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In the past, recruitment for RCTs has been by trial and error (112). More recently,
with the recognition of the importance of the use of appropriate recruitment strategies,
a number of different suggestions have been proposed to ensure adequate
recruitment (41). These include better planning and monitoring of recruitment, and
employment of recruitment methods such as the use of registries, occupational
screening, neighbourhood recruiting, digital telephoning, media promotion, community
campaigns, the offer of incentives, mass mailing and target mailing (40;41;43). Others
have assessed different methods of communication such as written information using
various writing styles (113;114), instructional audiotapes and videotapes, computer
programs, personal communication and by presenting or framing the information in a
certain way (115). Interestingly, full disclosure of information preserves patient
autonomy and improves recall and understanding of information, but may reduce
recruitment to clinical trials (116;117). Some have looked at different methods of
obtaining informed consent (118). Zelen proposed a controversial randomised
consent design whereby patients are randomised and consent is sought only from the
patients randomised to the experimental arm (119;120). However, the relative
effectiveness of each method remains unclear, and researchers continue to recruit by
trial and error, wasting precious time and resources on inefficient methods (41).
There have been very few studies on recruitment strategies used for paediatric trials.
Parental consent for trials is higher during a child’s acute illness (e.g. children
recruited from the emergency room and hospital admissions versus those identified
through outpatient records (70); the proportion of parents who enrolled their baby into
a clinical trial which required early entry was higher than those who enrolled in a
41
study which asked for later consent (71% vs. 43%) (121)) These differences in
consent rates may reflect parental response to a “sense of urgency” during their
child’s acute illness.Collet found the provision of group meetings for parents by highly
qualified physicians to discuss trial participation helpful (76).  The ethics of payment
for children’s participation in research to encourage recruitment is a contentious issue
(122;123), as almost 25% of paediatric trials offer payment to participants. This can
be in the form of reimbursement, compensation, appreciation or incentive payments.
There is concern that payment may distort parents’ and children’s decision-making.
However, non-payment is unfair and may add unnecessary financial obstacles to trial
participation. Very little is known about effective recruitment strategies for children.
The issue surrounding the recruitment of study participants for RCTs is a relatively
new area of enquiry with little known about the recruitment of children. It is imperative
to research this very important area as the demand for the inclusion of children in
RCTs increases.
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Chapter 3 - Recruitment strategies used to encourage participation
in randomised controlled trials (systematic review)
3.1 Introduction
There is increasing reliance on RCTs for clinical and regulatory decision making.
Recruitment of participants is often difficult (43), with poor recruitment reducing the
power of studies to detect significant intervention effects (124) causing delays,
increasing costs and ultimately leading to failure to complete trials in some cases
(44).
In the past, recruitment has been by trial and error (112). More recently, novel
strategies have been developed to facilitate adequate and timely recruitment
(124;125). The aim of this systematic review is to assess the effectiveness of different
methods of recruiting study participants into RCTs, which will help researchers in
planning trials, as the success of future RCTs depends on cost-effective means of
recruiting participants (126).
3.2 Methods
3.2.1 Inclusion and exclusion criteria
A systematic review of the literature was undertaken to include all experimental and
observational studies comparing methods of recruiting study participants to RCTs
(including 2 mock RCTs). Inclusion criteria were studies which compared methods of
recruiting study participants to the same RCT or trials, where consent rates and
proportion recruited by each method could be calculated. Exclusion criteria were
studies comparing recruitment at different locations using the same recruitment
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methods, studies where consent rates or proportion recruited by each method could
not be calculated, and recruitment to non-randomised studies (e.g. recruitment to
observational studies, questionnaires, health promotional activities and other
healthcare interventions). Where more than one publication of the same study exists,
the publication with the most complete data was included. It was necessary to expand
the inclusion criteria to observational studies for assessing strategies for enhancing
study participants for RCTs as there are very few RCTs of recruitment strategies for
trials (with only 6 identified at the time the search was first commenced in 2000).
The search was limited to recruitment for RCTs because the effectiveness of
recruitment strategies is hypothesised to vary depending on the type of research
studies for which participation is sought (e.g. for questionnaire response compared
with RCTs participation). Also, there is currently a Cochrane protocol for a systematic
review of strategies to improve recruitment to research studies (127) which was
submitted after 2000, when the search for this project was first commenced.
3.2.2 Searching
A comprehensive search of electronic databases included Medline (1966 to October
Week 5 2002), Embase (1980 to 2002 Week 45), and the Cochrane Library
(Cochrane Library 2002 Issue 4). Due to the time required to design appropriate
methods for data analysis, the initial search was updated (November 2002) closer to
the time of writing. The search strategy incorporated the “PICO” concept which
identified “population” (potential participants for RCTs participation), “intervention”
(recruitment strategies), “comparison“ (other recruitment strategies) and “outcome”
(consent or enrolment to RCTs). In Medline and Embase, the “population” was
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represented by “clinical trials” (exploded), the “intervention” and “comparison” were
represented by “recruit$” and the “outcome” was represented by “recruit$ or enrol$ or
accru$”. In the Cochrane Library, the “population” was represented by “random and
trial”, the “intervention” and “comparison” by “recruitment” and the outcome by
“consent or accrual” (see search strategy below).
For  MEDLINE  <1966 to October Week 5 2002>
and EMBASE <1980 to 2002  Week 46>
(recruit$ or enrol$ or accru$).tw.
exp Clinical Trials/
1 and 2
For the Cochrane Library (2002 Issue 4)
recruit* and (random* and trial*)   and (consent or accru*)
Reference lists of relevant studies, reviews and proceedings of scientific meetings
were also searched, and investigators known to be active in the field were contacted
to ask about unpublished trials (ie the “grey literature”). Although it is important to
attempt to identify unreported trials by searching the “grey literature”, as this reduces
publication bias, this method has limitations as it is difficult to know how much
unreported research exists. To further reduce bias, non-English language papers
were translated.
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3.2.3 Data extraction
Two reviewers independently screened all titles or abstracts identified by the search
strategy to identify potentially eligible studies which were then retrieved. Two
reviewers independently assessed each paper retrieved and extracted data using a
standard form (Appendix A), without blinding to authorship  (Figure 3.1, the flow
diagram for RCTs recruitment). The quality of the study and primary and secondary
outcome measures were sought. Disagreements were resolved by discussion with a
third reviewer.
For RCTs, the quality items allocation concealment, blinding of outcome assessors,
loss to follow up and intention to treat analysis were assessed separately using the
method developed by the Cochrane Renal Group (128). These quality items are
known to influence the true treatment effect  (129). A study was classified as quasi
RCT if allocation of recruitment method was clearly not random (e.g. sequential or
alternate allocation).
For observational studies, the quality items assessed were study type, blinding of
outcome assessors, loss to follow up (for prospective cohort studies only),
contamination between interventions, and adjustment for known confounders. These
quality items were chosen because that have been postulated to influence true
treatment effects (130-132)
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Figure 3.1: Flow diagram of RCTs recruitment
Exposure consent rate = trial participants/those exposed to recruitment method
Response consent rate = trial participants/those who initially responded to recruitment method
Assessment consent rate = trial participants/those exposed to the recruitment method who underwent
assessment for eligibility
The consent rate was the primary outcome of interest. Three consent rates were
calculated capturing distinct stages of the recruitment process (Figure 3.1):
· from the time potential participant’s were initially exposed to trial
information (exposed consent rate: the number of participants who enrolled
in the trial following exposure to that method divided by the total number of
potential participants exposed to that method):
· to when interested responders enquire about the trial (responder consent
rate: the number of participants who enrolled in the trial following exposure
to that method divided by the total number of responders who enquired
about the trial after exposure to that method):
(E) Exposure to recruitment
method
(A) Assessment for eligibility
(C) Consent for trial
participation
Nonresponse
Disinterested in
participation
Ineligible for
participation
(R) Initial response to
recruitment (enquire about RCT)
Exposed consent
rate = C/E
Responder
consent rate = C/R
Assessed consent
rate   = C/A
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· to when they are assessed for trial eligibility (assessed consent rate: the
number of participants who enrolled in the trial following exposure to that
method divided by the total number attending eligibility assessment after
exposure to that method).
The secondary outcome measures were proportion enrolled by each method and
recruitment cost per participant (ie the total recruitment cost for each method divided
by the number of participants who enrolled by that method) for individual studies.
3.2.4 Data analysis
For comparison of consent rates and proportions enrolled by each method, studies
were grouped into those that evaluated different categories of recruitment methods
and those that evaluated variations of strategies within the same category.  The
studies were grouped in this way in order to compare consent rates and proportions
between different categories of recruitment strategies where possible. For this group,
the relative risk (RR) for consent rates for individual studies and summary effect
measures were calculated in RevMan (133) using the random effects model, with RR
greater than 1.0 indicating a more effective strategy. Heterogeneity was analysed
using the Q statistic with an alpha of 0.1 used for statistical significance (134).
For studies evaluating recruitment strategy variations within the same category,
proportion recruited by each method and “exposed consent rate” were considered
together within each study. The “exposed consent rate” was considered significant if it
was outside the 95% confidence interval of other methods. For example, in Leader’s
study  the exposed consent rates for the 2 methods were 0.9 (95%CI 0.0,1.8) and 9.7
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(95% CI 7.3,12.1). These exposed consent rates are significantly different from each
other (see Table 3.5). The proportion enrolled by each method was considered
significant if it was beyond expectation for the number of methods used in the study
(i.e. 1/total number of methods used in the study). For example, in Leader’s study, the
proportion enrolled by the 2 methods were 7% and 93% when the expected
proportion if there was no difference in the methods would be 50% for each method.
The proportion enrolled by the 2 methods are significantly different from each other
(see Table 3.6). This method of combining “exposed consent rate” and proportion
recruited by each method was used for studies comparing variations of strategies
within the same category of recruitment method because summary effect measures
and meta regression of consent rates were difficult to measure in this group due to
the small numbers of studies comparing the same variations within a category. This
method was not used for studies comparing different categories of recruitment
strategies because there were insufficient studies that provide data for calculating
exposed consent rates in that group.
3.3 Results
3.3.1 Literature search
From 8602 unique titles, 50 eligible publications were identified assessing how over 4
million people were approached for RCTs participation, with 103,406 consenting to
participate (Figure 3.2).
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Figure 3.2: Search method for studies of recruitment strategies for systematic
review
1Not relevant = study did not appear relevant to recruitment for RCTs from reading of title and abstract.
2Not eligible = 53 did not compare recruitment methods, 15 consent rates or proportions recruited by
each method could not be calculated, 11 not about recruitment for RCTs, 3 comparing the same
recruitment methods at different locations, 2 comparing recruitment between different trials.
350 eligible studies (55 substudies) included.
3.3.2 Characteristics of included studies
The 50 eligible publications included data from 55 studies (Table 3.1, Appendix B).
Three publications evaluated more than one method for assessing recruitment (135)
and two reported 2 trials within the same publication (136;137).
Three publications evaluated more than one method for assessing recruitment (135)
and two reported 2 trials within the same publication (136;137).
8602 unique titles or abstracts
reviewed (after deduplication)
50 eligible studies3 included:
8 randomised controlled trials
2 quasi randomised controlled trials
13 prospective cohort studies
30 retrospective cohort studies
2 before after study
84 ineligible2
14 duplicates
8458 not relevant1
148 articles retrieved
3650 Medline 6608 Embase 296 Cochrane 1 additional study
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Eighty-seven different recruitment strategies were described which were grouped into
5 categories:
· personal methods (e.g. health care provider referral, recruitment by
research staff, “word of mouth” referrals);
· community approach (community presentations, fliers, posters and
screening at community sites, worksite recruitment);
· mailing (by mass mailing or direct mailing to people identified as
potentially eligible);
· media (e.g. radio, television, newspapers);
· and other (e.g. different styles of giving informed consent, framing
information about the trial, methods of information presentation and
comparison of recruiter dependent variables).
Thirty-five studies assessed different categories of recruitment methods (Table 3.2)
and twenty evaluated variations of strategies within one category (Table 3.3).
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Table 3.1: Characteristics of included studies in the systematic review
STUDY
TYPE
AUTHOR HEALTH PROBLEM STUDIED TRIAL
TYPE
TRIAL DESCRIIPTION Enrolled
(n)
Approached
for RCT (N)
Fleissig 2001 Cancer multiple Multiple RCTs of cancer therapies - chemotherapy, radiotherapy, endocrine, immune therapy and screening  in adult cancer patients 205 265
Martinson 2000 Smoking prevention Agreement to participate in a smoke cessation and prevention trial for adolescents 1560 4200
Myles 1999 Mock trial for elective surgical patients mock trial Mock trial of an anaesthetic drug in adults scheduled for elective surgery 429 791
Valanis2 1998 Lung cancer prevention Beta carotene and retinyl palmitate for the prevention of lung cancer in high risk individuals (563) (22546)
Aaronson 1996 Cancer treatment Phase II or III clinical trials for cancer patients 146 346
Gallo 1995 Mock trial for healthy subjects mock trial Mock trial of unnamed disease for healthy subjects attending a scientific exhibition 1623 2035
Llewellyn-Thomas 1995 Mock trial for oncology patients mock trial Mock trial for outpatients cancer patients 52 100
RCT
Wadland2 1990 Smoking treatment Nicotine gum for smoking cessation (52) (274)
Wragg 2000 Mock trial for healthy subjects mock trial Mock trial of hormone replacement therapy for women 22 50QRCT
Miller 1999 Depression treatment Psychotherapy and antidepressants for chronically depressed patients 50 347
Folmar 2001 Coronary heart disease prevention Effect of oestrogen vs oestrogen & progesterone vs placebo on coronary atherosclerosis in postmenopausal women. 305 73327+
Gill 2001 Functional decline and disability in the elderly prevention A home-based physical therapy intervention trial to prevent functional decline in frail elderly 188 4637
Bell-Syer 2000 Lower back pain treatment Trial of exercise class for improving subacute lower back pain in primary care patients 187 1588
Margitic 1999 Physical inactivity prevention Interventions for increasing physical activity in sedentary adults 874 3908
Fitzgibbon 1998 Cardiovascular disease in African-Americans prevention A community intervention to reduce fat intake in working class black people 420 5180
Goodman 1998 Lung cancer prevention Beta carotene and retinyl palmitate for the prevention of lung cancer in high risk individuals 13186 1216549+
Valanis1 1998 Lung cancer prevention Beta carotene and retinyl palmitate for the prevention of lung cancer in high risk individuals (1502) (42559)
Adams 1997 Management of frail elderly prevention Trial of diagnosis and treatment of the elderly through outpatient geriatric assessment units vs routine physician care 442 1265
Garcia-Losa 1995 Asthma treatment Drug treatment for mild to moderate asthma 24 465
King 1994 Cardiovascular disease prevention Strategies for increasing activity in sedentary people age 50-65 357 2325
Silagy 1991 Cardiovascular disease prevention Low dose aspirin for preventing cardiovascular disease in the elderly 400 697
Wadland1 1990 Smoking treatment Nicotine gum for smoking cessation 94 2268
PCS
Leader 1978 Cerebroarteriosclerosis treatment Vasodilator effects on the psychophysiological function of elderly people with moderate cerebroarteriosclerosis 60 1030
Kusek 2002 Cancer prevention Doxazosin/finasteride combinations vs placebo in preventing benign prostatic hyperplasia progression 2931 16723
Tworoger 2002 Obesity treatment Moderate intensity exercise vs stretching in affecting body changes obese postmenopausal women 173 103577+
Cambron 2001 Dysmenorrhoea treatment Lower back spinal manipulation therapy vs low force mimic in subjective reduction of dysmenorrhhoea 138 2312
Wright 2001 Hypertension treatment Antihypertensive and lipid lowering therapy for high risk hypertensives 42419 unknown
Chung 2000 Prostatic cancer prevention Finasteride for preventing prostatic cancer in high risk males 82 184
Theoret 2000 Low birth weight prevention Program to reduce the incidence of low birth weight infants for pregnant women with very low socioeconomic status 439 1272
Appel 1999 Hypertension prevention Diet modification on BP of healthy subjects with high normal BP 459 710000+
Camerini 1999 Breast cancer prevention Fenretinide for the prevention of contralateral breast cancer in breast cancer patients. 1815 4030
Cooler 1999 Depression treatment Trial of antidepressant medications for depressed elderly 24 257
Cosgrove 1999 Cardiovascular disease prevention Trial of antihypertensive drugs  for hypertensive elderly 4736 343554
Arnold 1989 Cancer prevention Synthetic retinoid etretinate vs placebo in reducing  level of bronchial atypia in heavy smokers 80 905
Lewis 1998 Obesity prevention Reduction of dietary fat in postmenopausal women 2208 12434
Coleman 1997 Falls and disability in elderly African-
Americans
prevention A community based intervention for reducing disability and falls in African-American elderly 120 262
Whelton 1997 Hypertension treatment Weight loss and sodium reduction following withdrawal of antihypertensives for well controlled hypertensive elderly 975 8787
Isaacman2 1996 Bacteraemia diagnostic Blood culture collection strategies for detecting bacteriaemia in febrile children (157) (532)
Anderson 1995 Diabetes care prevention Trial of an intensive diabetes program for elderly diabetics 103 429
Hollis 1995 Hypertension prevention Weight loss and sodium reduction in reducing hypertention in high risk population 2382 3089726
Maurer 1995 Knee osteoarthritis treatment Quadriceps strength training for older adults with knee osteoarthritis 108 263
Moon1 1995 Skin cancer prevention Retinol for the prevention of skin cancer among high risk individuals 2800 11000+
Moon2 1995 Skin cancer prevention Retinol for the prevention of skin cancer among high risk individuals 525 1482
Piotrowski 1994 Crack cocaine dependence treatment Crack-cocaine dependence treatments (drugs and psychotherapy combinations) for crack-cocaine dependent males 94 379
Bjornson-Benson 1993 Chronic obstructive lung disease prevention Intervention program (smoking cessation and bronchodilators) to reduce the rate of lung function decline in patients with early chronic obstructive
pulmonary disease (duplicate).
(189) (1626)
Carew1 1993 Congestive heart failure treatment ACE inhibitor vs placebo in treatment of patients with congestive heart failure 1647 55069
Carew2 1993 Congestive heart failure prevention ACE inhibitor vs placebo in preventing congestive heart failure in patients with left ventricular dysfunction 2502 (see Carew1)
Connett 1993 Chronic obstructive lung disease prevention Intervention program (smoking cessation and bronchodilators) to reduce the rate of lung function decline in patients with early chronic obstructive
pulmonary disease.
5887 (73684)
Kusek 1993 Renal failure prevention 2 studies of different levels of protein/phosphorus intake and BP in reducing rate of decline in renal function in patients with chronic renal disease. 840 4300
Rudick 1993 Chronic obstructive lung disease prevention Intervention program (smoking cessation and bronchodilators) to reduce the rate of lung function decline in patients with early chronic obstructive
pulmonary disease (duplicate).
(577) 171602
Burns 1990 Urinary incontinence treatment Behaviour treatment for stress urinary incontinence in elderly females 135 1042
Schoenberger 1987 Coronary heart disease prevention Aspirin for the prevention of coronary heart disease in acute myocardial infarct patients 4524 5396+
RCS
*Anon 1983 Coronary heart disease prevention Lowering of plasma cholesterol to reduce coronary heart disease in males 3810 436679
Isaacman1 1996 Bacteraemia diagnostic Blood culture collection strategies for detecting bacteriaemia in febrile children 166 534BAS
Brewster 2002 Cancer prevention Single visit cervical cancer prevention program vs usual care for low income Latino women with abnormal pap smears. 940 6041+
Total 103,481 4,183,257
RCT = randomised controlled trials, QRCT = quasi randomised controlled trials, PCS = prospective cohort study, RCS = retrospective cohort study, BAS = before after study. (  ) indicates numbers not included in total
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RECRUITMENT METHODSSTUDY
TYPE
AUTHOR
MEDIA COMMUNITY BASED MAILING PERSONAL APPROACH
Folmar Community presentations, fliers at community sites, hospital screening Mass mailing & target mailing
Bell-Syer Computerized medical record review
with mailing to eligible patients
Referral by primary care physicians during routine office visit
Margitic Questionnaires in physicians' waiting room Mass mailing Referral by primary care physicians during routine office visit, telephone by research
staff
Fitzgibbon House to house canvassing Telephone by research staff
Goodman Magazines, local newspapers, radio & TV Posters at community sites Mass mailing, mailed advertising
Adams Magazines, local newspapers, radio & TV Community presentations, fliers at community sites Mailing to people who may know of
potential participants
Referral by healthcare provider, social service agencies and word of mouth, approach
by research staff
Garcia-Losa Target mailing By healthcare provider during office visit, phoned by nurse to attend standard visit,
phoned by trial co-ordinator to participate in trial
King Newspapers, radio & TV + posters Random digit dial telephone survey
PCS
Silagy Community presentations and brochures and posters at community sites +
newspapers, radio
Target mailing & mass mailing using
electoral roll lists
Kusek 2002 Newspaper, newsletter, radio & TV Community events, posters/display Mass mailing Referrals, word of mouth
Tworoger Newspapers, newsletters, TV and radio Includes community presentations and fliers at community sites Mass mailing
Cambron Newspapers, radio & TV Community college newspapers, posters, electronic sign Word of mouth
Chung Newspapers, newsletters & TV Community presentations, posters, community surveys, other methods
including flies with paychecks
Referral by doctor, word of mouth
Theoret Posters and pamphlets at community sites Mass mailing Referral by healthcare provider and others including word of mouth
Appel Newspapers, newsletters, radio & TV Coupon distribution, screening events and presentations Mass mailing Word of mouth and approaching prior study participants
Camerini Direct mailing or personal invitations to
eligible patients identified by medical
record review
Referral by healthcare provider during hospitalization or at routine follow up visit
Cooler Newspapers, newsletters, TV & radio Flyers at community sites, community and hospital presentations Referral by healthcare provider, social service agency, religious organization and
word of mouth
Cosgrove Screening in the general community, at senior citizen centers, shopping
malls, nutrition sites, drug stores, social security office and libraries
Mailing using electoral roll &
commercially purchased lists
Lewis Magazines, newspapers, radio and TV Community presentations and brochures at community sites Mass mailing Referral by healthcare provider + word of mouth
Coleman Magazines and community newspapers +
flyers and brochures at community sites
Other methods including community presentations, TV media campaign and
observing the trial in progress
Phonathon using a bank of phones and personal phone calls and by word of mouth
Whelton Newspapers radio and TV + coupons and
placemats distribution
Screening at community sites, recruiting previous research participants,
worksite presentations, bill board and bus advertisements
Mass mailing Referral by trial participants and encouraging referral by healthcare providers
(medical presentations, flyers and brochures, recruitment material in clinical areas)
Anderson Newspapers Posters and brochures at community sites, community presentations Target mailing Referral by previous research participants and letter campaign for encouraging
referral by healthcare providers
Hollis Newspapers, radio & TV Screening at community sites Mass mailing Others including referral by healthcare providers and word of mouth + posters &
brochures
Moon1 Newspapers, radio & TV + posters and
fliers at community sites
Referral by dermatologists during routine office visit
Moon2 Newspapers, radio & TV + posters and
fliers at community sites
Review of skin cancer registry with
invitation to potentially eligible patients
Referral by dermatologists during routine office visit
Maurer Newspapers, specialty publications, radio +
TV
Posters at hospital clinics Target mailing Letter campaign to encourage referrals by healthcare providers and by word of mouth
Piotrowski Newspapers & radio Mailed fliers + posters on buses Recruitment of inpatients by research assistant  and referral by other treatment
programs, the courts and by word of mouth
Bjornson-
Benson
Newspaper, radio & TV Brochures at community sites + worksite screening and promotion Mass mailing word of mouth (with prizes incentives)
Connett Newspaper, radio & TV Screening at community sites + worksite screening Mass mailing Others including referral  from clinical laboratories and physician referral
Kusek 1993 Newspaper & TV Referral  by health care provider and word of mouth
Rudick Newspapers, radio & TV Shopping mall recruitment, community screening and trial promotion,
worksite screening and other methods including referrals (health care
provider and trial participants), mailed advertisements, promotional material
at community sites and campaign for encouraging referrals
Mass mailing Phone follow up of people who received mailing
Burns Regional and suburban newspapers + TV Brochures and posters at community sites Referral by healthcare provider
Schoenberger Newspapers, radio, TV Medical record review with personal invitation by trial staff or their own physician to
eligible patients, referral by private physicians or by physicians directly involved in the
study during routine office visits
RCS
Anon Mass media Community screening + worksite screening Mass mailing Referral by doctors, other clinical studies, blood bank + clinical laboratories
BAS Brewster Newspapers and fliers Target mailing
PCS = prospective cohort study, RCS = retrospective cohort study, BAS = Before after study. Mass mailing = nondirect mailing to people on lists etc, Direct mailing = mailing to people identified as potentially eligible
Table 3.2: Descriptions of strategies used in studies evaluating different categories of recruitment methods
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Table 3.3: Descriptions of strategies used in studies evaluating variations in one category of recruitment method
STUDY
TYPE
AUTHOR RECRUITMENT METHODS
TYPE OF CONSENT
Myles One sided informed consent - random
assignment for participants, standard
care for nonparticipants
Prerandomised to experimental drug -
experimental drug for participants,
standard care for nonparticipants
Prerandomised to standard drug -
standard drug for participants,
experiemental drug for nonparticipants
One sided physician modified informed
consent - patients are told that the
physician believes that the experimental
drug may be superior to the standard
drug, and if they give consent, they have
a greater chance of receiving the
experimental drug
One sided patient modified informed
consent - patients are told that they are
allowed to increase or decrease their
chance of receiving the new
experimental drug after consenting
RCTs
Gallo One sided informed consent - random
assignment for participants, standard
care for nonparticipants
Prerandomised to experimental drug -
experimental drug for participants,
standard care for nonparticipants
Prerandomised to standard drug -
standard drug for participants,
experiemental drug for nonparticipants
Two sided informed consent - random
assignment for participants, choice of
treatments for nonparticipants
FRAMING OF  RECRUITMENT INFORMATION
QRCT Wragg Explicit information  framed in a way which provide the current best estimates of effect of the
experimental treatment
Ambiguous information framed in a way which emphasised the current state of uncertainty about the
relative costs and benefits of the experimental treatment
PCS Leader Normative approach emphasising data gathering Symptomatic approach focusing on early diagnosis and treatment
INFORMATION PRESENTATION
Aaronson Standard informed consent Additional phone based contact with oncology nurse
Llewellyn-
Thomas
Tape recording of reading of the trial information Interactive computer program with participant actively involved in the information search process
RCTs
Wadland2 Patients reading the trial information themselves Study coordinator reading and explaining the study to patients
RCS Arnold Daily newspaper  Weekly newspaper TV news Community TV Radio
MAILING
Martinson Standard mailing with no
incentives
Mailing with prepaid $2 cash Mailing with $15 cash contingent
on response
Mailing with $200 prize drawRCTs
Valanis2 Mailing of the full recruitment
packet
Advanced postcard one week
prior to mailing of recruitment
packet
PCS Valanis1 First class postage with a letter
signed by the principal
investigator of the trial
First class postage with a letter
signed by the medical director of
the insurance company
First class non profit postage with
a letter signed by the principal
investigator of the trial
First class non profit postage with
a letter signed by the medical
director of the insurance company
First class postage of single page
questionnaire mailer
Bulk rate postage of a single page
questionnaire mailer
RECRUITER DEPENDENT VARIABLES
RCTs Fleissig Standard - doctors recruiting patients without being shown patient's responses to questionnaire regarding
personal preferences and trial participation
Doctors shown patients’ responses to questionnaire regarding personal preferences and trial
participation before recruiting patients for trial
QRCT Miller Recruitment by senior investigator Recruitment by research assistance
Gill Referral by primary care physicians during routine office visit Identified by medical records, phoned then assessed in the home by research staffPCS
Wadland1 By a private family practice located in a semi-rural town By an academic general internal medicine practice with previous research experience located in the
University Health Center
Wright Referral by private solo practices Referral by private group
practices
Referral by health maintenance
organisations
Referral by community health
centres
Referral by university academic
medical centres
Referrals from department of
veteran affairs medical centres
Isaacman2 Recruitment by investigator physician Recruitment by research nurse
Carew1 Radionuclide lab Cardiac catheter lab Echocardiogram lab Other referral
RCS
Carew2 Radionuclide lab Cardiac catheter lab Echocardiogram lab Other referral
BAS Isaacman1 Recruitment by physician investigator Addition of a research nurse
RCT=randomised controlled trial,    QRCT=quasi-randomised controlled trial,    PCS=prospective cohort study    RCS=retrospective cohort study,    BAS=before after study
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3.3.3 Study quality
Of the 8 RCTs and 2 quasi RCTs included, only 1 had adequate allocation concealment,
2 mentioned loss to follow up and none mentioned blinding. It was unclear whether
intention to treat analysis was used in any studies.
Of the 45 observational studies, exposure to the different recruitment methods was
impossible to measure in the retrospective cohort studies, and may be difficult to
measure for some methods such as media or community approach in any study.
Although outcome measurements were similar between interventions in each study
(enrolment or intention to participate in a RCT), none mentioned blinding of outcome
assessors. In 8 studies, only the proportion recruited by each method was provided (with
no data provided for consent rate calculations). Although known confounders (e.g.
gender, level of education, socio-economic status) were acknowledged in some studies,
they were not adjusted for in any of the studies. Contamination between interventions
was likely in at least 28 studies where subjects could potentially be exposed to multiple
recruitment methods (e.g. media and community approach). Of the prospective cohort
studies, only 3 provided data for calculating exposure to the recruitment methods and
only 1 mentioned loss to follow up.
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3.3.4 Consent rates and proportions enrolled by each method in studies
comparing different categories of recruitment methods
3.3.4.1 Consent rates (Table 3.4.1 to 3.4.4 and Figure 3.4: Forest plots for consent
rates comparing different categories of recruitment methods ):
Although the exposed consent rate most closely reflects the true effectiveness of
exposure to the recruitment method, only 6 studies compared exposed consent rates.
Health care provider referral had a higher consent rate than target mailing: RR 1.84
(1.08, 3.13). In the 2 studies that assessed media, media had lower consent rates than
all other methods (research staff recruitment versus media RR: 604.90 (354.63,
1031.78); community approach versus media RR: 106.22 (6.02, 1872.87) and mailing
versus media RR: 21.33 (14.08, 32.32)).  The denominator used for media is based on
expected audience numbers for radio and television and circulation for printed media. As
radio and television audience and readers of newspapers may not necessarily have
seen or heard the recruitment material, the denominator used may not be true, and may
partly explain the high RR.
Seventeen studies compared responder consent rates. Health care provider referrals
again had higher consent rates than other methods (health care provider referral versus
community presentation: RR 1.37 (1.06; 1.78); health care provider referral versus
worksite approach: RR 25.20 (20.19, 31.45); health care provider referral versus general
community approach: RR 2.53 (0.46, 14.05) not statistically significant; health care
provider referral versus mailing: RR 3.29 (1.26, 8.60); health care provider referral
versus media: RR 2.66 (1.31, 5.41)).
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Of the 16 studies comparing assessed consent rates, no significant difference in consent
rates by method of recruitment was found. This consent rate was the least useful for
evaluating the effectiveness of recruitment strategies as it measures eligibility of
potential participants and not their willingness to participate in the trial. (See Figure 3.4
which compares exposed, responder and assessed consent rates between the different
categories of recruitment methods).
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Table 3.4.1: Consent rates and proportions by personal methods for studies
evaluating different categories of recruitment methods (Part 1)
STUDY
TYPE
AUTHOR Method # Enrolled Exposed Consent Rate Respond Consent Rate Assessed Consent Rate %
Recruited
by
Method
Folmar
Bell-Syer HCP referral 104 19 ( 16 , 23 ) 56
Margitic* HCP referral 12 1
Research staff 189 22
Fitzgibbon Research staff 117 7 ( 6 , 9 ) 28
Goodman
Adams HCP referral 85 45 ( 38 , 52 ) 19
Research staff 26 7 ( 4 , 10 ) 65 ( 50 , 80 ) 6
Garcia-Losa HCP referral 5 13 ( 2 , 24 ) 21
Research staff 7 3 ( 1 , 5 ) 16 ( 5 , 26 ) 27 ( 10 , 44 ) 29
Other 3 6 ( -1 , 13 ) 25 ( 1 , 50 ) 25 ( 1 , 50 ) 13
King Research staff 214 1 ( 1 , 1 ) 2 ( 1 , 2 ) 11 ( 10 , 13 ) 60
Silagy
PCS
Kusek 2002 HCP referral 280 41 ( 37 , 44 ) 78 ( 73 , 82 ) 10
WOM 122 35 30 , 40 81 ( 75 , 88 ) 4
Tworoger
Cambron WOM 27 7 ( 4 , 9 ) 41 ( 29 , 53 ) 20
Chung HCP referral 4 40 ( 10 , 70 ) 5
WOM 5 22 ( 5 , 39 ) 6
Theoret* HCP referral 154 35
WOM 184 42
Appel* WOM 90 20
Camerini HCP referral 990 54 ( 52 , 56 ) 55
Cooler HCP referral 2 20 ( -5 , 45 ) 8
WOM 0 0 ( 0 , 0 ) 0
Other 1 11 ( -9 , 32 ) 4
Cosgrove
Lewis HCP referral 183 10 ( 9 , 12 ) 8
Coleman Research staff 40 6 ( 4 , 8 ) 11 ( 8 , 15 ) 40 ( 30 , 50 ) 33
WOM 31 ( ) 74 ( 61 , 87 ) 26
Whelton WOM 23 12 ( 8 , 17 ) 30 ( 20 , 40 ) 2
Other 9 21 ( 9 , 34 ) 47 ( 25 , 70 ) 1
Anderson WOM 3 21 ( 0 , 43 ) 3
Other 4 19 ( 2 , 36 ) 4
Hollis Other 105 4
Maurer* HCP referral 32 31
WOM 0 0
Other 0 0
Moon1 HCP referral 279 100 ( 100 , 100 ) 13
Moon2 HCP referral 187 100 ( 100 , 100 ) 44
Piotrowski Research staff 21 10 ( 6 , 15 ) 22
WOM 19 54 ( 38 , 71 ) 20
Other 30 44 ( 32 , 56 ) 32
Bjornson-
Benson
WOM 25 13 ( 8 , 17 ) 13
( )
Connett Other 791 9 ( 8 , 9 ) 13
Kusek 1993* HCP referral 378 56
WOM 47 7
Rudick Research staff 114 6 ( 5 , 7 ) 22
Burns HCP referral 0 0 ( 0 , 0 ) 0 ( 0 , 0 ) 0
Schoenberger* HCP referral 732 18
Research staff 1828 44
Anon HCP referral 161 14 ( 12 , 16 ) 29 ( 25 , 33 ) 5
RCS
Other 1229 1 ( 1 , 1 ) 23 ( 22 , 25 ) 35
BAS Brewster
* Consent rates cannot be calculated, PCS = prospective cohort study, RCS = retrospective cohort study, BAS = before after study, HCP = health care provider, WOM = word of mouth
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Table 3.4.2: Consent rates and proportions by community methods for studies
evaluating different categories of recruitment methods (Part 2)
STUDY
TYPE
AUTHOR Method # Enrolled Exposed Consent Rate Respond Consent Rate Assessed Consent Rate %
Recruited
by
Method
Folmar General 198 6 ( 5 , 7 ) 2 ( 2 , 2 ) 65
Bell-Syer
Margitic* General 284 33
Fitzgibbon Presentations 303 8 ( 8 , 9 ) 72
Goodman General 57 ( ) 42 ( 34 , 50 ) 42 ( 34 , 50 ) 0
Adams General 5 0 ( 0 , 1 ) 42 ( 14 , 70 ) 1
Presentations 223 5 ( 5 , 6 ) 32 ( 29 , 36 ) 50
Garcia-Losa
King
Silagy General 100 83 ( 77 , 90 ) 25
PCS
Kusek 2002 General 364 27 ( 25 , 30 ) 75 ( 71 , 79 ) 13
Tworoger General 12 3 ( 1 , 5 ) 18 ( 99 , 27 ) 7
Cambron General 20 6 ( 4 , 9 ) 35 ( 22 , 47 ) 15
Chung General 0 0 ( 0 , 0 ) 0
Presentations 7 54 ( 27 , 89 ) 9
Theoret* General 24 5
Appel* General 109 24
Camerini
Cooler General 1 5 ( -5 , 15 ) 4
Presentations 1 17 ( -13 , 47 ) 4
Cosgrove General 678 0 ( 0 , 0 ) 14
Lewis General 51 12 ( 9 , 15 ) 2
Coleman General 10 71 ( 48 , 95 ) 8
( )
Whelton General 57 7 ( 5 , 9 ) 28 ( 22 , 34 ) 6
Anderson General 3 13 ( -1 , 27 ) 3
Presentations 0 0 ( 0 , 0 ) 0
Hollis General 275 0 ( 0 , 1 ) 12
Maurer* General 19 18
Moon1
Moon2
Piotrowski General 22 33 ( 22 , 44. ) 23
Bjornson-
Benson
General 36 10 ( 7 , 13 ) 19
Worksite 23 8 ( 5 , 11 ) 12
Connett General 406 4 ( 4 , 4 ) 7
Worksite 458 5 ( 4 , 5 ) 8
Kusek 1993*
Rudick General 69 13
Worksite 103 20
Burns General 26 8 ( 5 , 10 ) 8 ( 5 , 10 ) 20
Schoenberger*
Anon General 535 1 ( 1 , 1 ) 21 ( 19 , 22 ) 15
RCS
Worksite 904 1 ( 1 , 1 ) 18 ( 17 , 19 ) 26
BAS Brewster
* Consent rates cannot be calculated, PCS = prospective cohort study, RCS = retrospective cohort study, BAS = before after study
59
Table 3.4.3: Consent rates and proportions by mailing strategies for studies
evaluating different categories of recruitment methods (Part 3)
STUDY
TYPE
AUTHOR Method # Enrolled Exposed Consent Rate Respond Consent Rate Assessed Consent Rate %
Recruited
by
Method
Folmar Mass mailing 40 0 ( 0 , 0 ) 0 ( 0 , 0 ) 36 ( 27 , 45 ) 13
Direct mailing 67 1 ( 0 , 1 ) 1 ( 1 , 1 ) 28 ( 22 , 33 ) 22
Bell-Syer Direct mailing 83 8 ( 6 , 10 ) 44
Margitic* Mass mailing 379 44
Fitzgibbon
Goodman Mass mailing 12240 1 ( 1 , 1 ) 10 ( 9 , 10 ) 10 ( 9 , 10 ) 95
Adams Direct mailing 52 0 ( 0 , 0 ) 37 ( 29 , 46 ) 12
Garcia-Losa Direct mailing 9 5 ( 2 , 9 ) 13 ( 5 , 21 ) 45 ( 23 , 67 ) 38
King
Silagy Mass mailing 100 6 ( 5 , 7 ) 65 ( 57 , 73 ) 25
PCS
Direct mailing 200 18 ( 16 , 21 ) 47 ( 43 , 52 ) 50
Kusek 2002 Mass mailing 783 11 ( 10 , 12 ) 77 ( 74 , 79 ) 27
Tworoger Mass mailing 144 0 ( 0 , 0 ) 2 ( 2 , 2 ) 13 ( 11 , 15 ) 83
Cambron
Chung
Theoret* Mass mailing 77 18
Appel* Mass mailing 194 42
Camerini Direct mailing 825 38 ( 36 , 40 ) 45
Cooler
Cosgrove Mass mailing 4058 0 ( 0 , 0 ) 3 ( 3 , 3 ) 86
Lewis Mass mailing 1097 11 ( 10 , 12 ) 50
Coleman
Whelton Mass mailing 737 0 ( 0 , 0 ) 11 ( 11 , 12 ) 32 ( 30 , 34 ) 76
Anderson Direct mailing 3 0 ( 0 , 0 ) 2 ( 0 , 4 ) 9 ( -1 , 18 ) 3
Hollis Mass mailing 1745 0 ( 0 , 0 ) 2 ( 2 , 2 ) 73
Maurer* Direct mailing 7 7
Moon1
Moon2 Direct mailing 75 68 ( 59 , 76 ) 18
Piotrowski
Bjornson-
Benson
Mass mailing 30 20 ( 14 , 26 ) 16
Connett Mass mailing 2180 9 ( 9 , 10 ) 37
Kusek 1993*
Rudick Mass mailing 193 6 ( 6 , 7 ) 37
Burns
Schoenberger*
Anon Mass mailing 212 1 ( 1 , 1 ) 17 ( 15 , 19 ) 6
RCS
BAS Brewster Direct mailing 405 26 ( 24 , 29 ) 43
* Consent rates cannot be calculated, PCS = prospective cohort study, RCS = retrospective cohort study, BAS = before after study
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Table 3.4.4: Consent rates and proportions by media for studies evaluating
different categories of recruitment methods (Part 4)
STUDY
TYPE
AUTHOR Method # Enrolled Exposed Consent Rate Respond Consent Rate Assessed Consent Rate %
Recruited
by
Method
Total
recruited
in the
study
Folmar 305
305
Bell-Syer 187
Margitic* 864
864
Fitzgibbon 420
Goodman Media 622 0 ( 0 , 0 ) 31 ( 29 , 33 ) 31 ( 29 , 33 ) 5 12919
Adams Media 51 0 ( 0 , 0 ) 30 ( 23 , 36 ) 12 442
442
Garcia-Losa 24
24
24
King Media 143 32 ( 28 , 36 ) 40 357
Silagy 400
PCS
400
Kusek 2002 Media 1325 21 ( 20 , 22 ) 78 ( 77 , 80 ) 46 2902
2902
Tworoger Media 17 3 ( 2 , 5 ) 21 ( 12 , 29 ) 10 173
Cambron Media 90 6 ( 5 , 7 ) 38 ( 32 , 44 ) 66 137
Chung Media 66 50 ( 42 , 59 ) 80 82
82
Theoret* 439
439
Appel* Media 66 14 459
Camerini 1815
Cooler Media 19 10 ( 6 , 14 ) 79 24
24
24
Cosgrove 4736
Lewis Media 851 13 ( 12 , 14 ) 39 2182
Coleman Media 39 38 ( 28 , 47 ) 33 120
120
Whelton Media 149 ( 10 , 14 ) 31 ( 27 , 35 ) 15 975
975
Anderson Media 83 27 ( 22 , 32 ) 86 96
96
Hollis Media 257 11 2382
Maurer* Media 45 44 103
103
103
Moon1 Media 1790 16 ( 15 , 17 ) 87 2069
Moon2 Media 162 13 ( 11 , 14 ) 38 424
Piotrowski Media 2 33 ( -4 , 71 ) 2 94
94
94
Bjornson-Benson Media 75 12 ( 9 , 14 ) 40 189
189
Connett Media 2052 10 ( 10 , 10 ) 35 5887
5887
Kusek 1993* Media 245 37 670
670
Rudick Media 42 8 ( 6 , 11 ) 8 521
521
Burns Media 105 16 ( 13 , 18 ) 16 ( 13 , 18 ) 80 131
Schoenberger* Media 1561 38 4121
4121
Anon Media 437 2 ( 2 , 3 ) 23 ( 21 , 25 ) 13 3478
RCS
3478
BAS Brewster Media 535 51 ( 48 , 54 ) 57 940
* Consent rates cannot be calculated, PCS = prospective cohort study, RCS = retrospective cohort study, BAS = before after study
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3.3.4.2 Proportions enrolled by each method (Figure 3.3):
The proportion enrolled by the different categories varies between studies. Generally
studies have higher absolute numbers of participants enrolled by methods that expose
large numbers of potential participants to trial information irrespective of the consent rate
for that method. For example, in one study 27% of participants were recruited by mass
mailing and 46% by media compared with 10% by health care provider referral because
many more potential participants were exposed to trial information by mailing and media,
despite the higher consent rate for health care provider referral (11.1%, 20.9% and
40.6% responder consent rates respectively).
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Figure 3.3: Proportions enrolled by each method for studies comparing different categories of recruitment methods
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3.3.5 Consent rates and proportions enrolled by each method in studies
comparing variations of methods within one category (Tables 3.5, 3.6)
Effective strategies identified were framing of recruitment information (e.g. information
emphasising uncertainty was more effective than providing estimates of effect, and
focusing on early diagnosis and treatment was more effective than emphasising data
collection) (115;138), the addition of monetary incentives with mailing (irrespective of
size of the incentive) (139), the use of an interactive computer program to learn about
the trial compared with listening to an audio-tape of trial information (140), mailing of
recruitment material accompanied by a letter from the trial investigator (141), and
informing doctors of patients’ preferences (142) (with both high consent rates and
proportions enrolled). Although the addition of a research nurse for supplementing
recruitment (by being more available, and to act as a reminder about the existence of
the trials) is beneficial (135), the addition of a nurse for the purpose of information
provision is uncertain (59;105). Methods that did not influence proportions and consent
rates include advance postcard prior to mailing of recruitment material (141) and
different methods of informed consent (118;143). In studies where exposed consent
rates could not be calculated, proportions enrolled by each method may be associated
with exposure of potential participant by the method.
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Table 3.5: Consent rates and proportions by strategy for studies evaluating variations within one category of recruitment
method
STUDY
TYPE
AUTHOR Method #
Enrolled
Exposed
Consent Rate
Responder
Consent Rate
Assessed
Consent Rate
% by
Method
Method #
Enrolled
Exposed
Consent Rate
Respond
Consent Rate
Assessed
Consent Rate
% by
Method
Total
Recruited
in Study
FRAMING
QRCT Wragg Providing estimates of effect 8 30.8 (13.0, 48.5) 30.8 (13.0,48.5) 36 Emphasising uncertainty 14 58.3 (38.6, 78.1) 58.3 (38.6, 78.1) 64 22
PCS Leader Emphasising data gathering 4 0.9 (0.0,1.8) 0.9 (0.0, 1.8) 2.7 (0.1, 5.2) 7 Focusing on early diagnosis and treatment 56 9.7 (7.3, 12.1) 9.7 (7.3, 12.1) 26.7 (21.5, 33.9) 93 60
INFORMATION PRESENTATION
RCT Aaronson Control 78 86.7 (79.6, 93.7) 86.7 (79.6, 93.7) 86.7 (79.6, 93.7) 53 Additional contact with oncology nurse 68 75.6 (66.7, 84.4) 75.6 (66.7, 84.4) 75.6 (66.7, 84.4) 47 146
Wadland2 Control 25 47.2 (33.7, 60.0) 48 Additional study coordinator reading and
explanation
27 52.9 (39.2, 66.6) 52 52
Llewellyn-
Thomas
Tape recording of trial information 21 42.0 (28.3, 55.7) 40.4 Interactive computer program 31 62.0 (48.5, 75.5) 59.6 52
RCS Arnold Daily newspaper 39 11.8 (8.3, 15.3) 51 Weekly newspaper 13 9.5 (4.6, 14.4) 17 76
Community TV 1 3.3 (-3.1, 9.8) 1 TV news 12 9.4 (4.3, 14.4) 16
Radio 11 9.6 (4.2, 14.9) 14
MAILING
RCT Martinson Mailing with no incentive 288 27.4 (24.7, 30.1) 59.6 (55.3, 64.0) 18 Prepaid $2 cash 423 40.3 (37.3, 43.3) 65.1(61.4, 68.7) 27 1560
$15 cash contingent on response 452 43.0 (40.1, 46.0) 62.7 (59.2, 66.2) 29 $200 prize draw 397 37.8 (34.9, 40.7) 67.4 (64.6, 71.2) 25
Valanis2 Full recruitment packet 259 2.3 (2.0, 2.6) 5.3 (4.7, 6.0) 46 Advanced postcard prior to recruitment packet 304 2.7 (2.4, 3.0) 5.6 (5.0, 6.2) 54 563
PCS Valanis1 First class postage & letter from trial investigator 369 2.0 (1.8, 2.2) 3.6 (3.2, 3.9) 25 First class postage & letter from medical
director
138 1.2 (1.0, 1.4) 3.3 (2.8, 3.9) 9 1502
First class non profit postage & letter from trial
investigator
302 2.5 (2.2, 2.8) 4.1 (3.7, 4.6) 20 First class non profit postage & letter from
medical director
281 1.1 (1.0, 1.2) 3.9 (3.4, 4.3) 19
First class postage of questionnaire 280 1.0 (0.9, 1.1) 3.3 (2.9, 3.7) 19 Bulk rate postage of questionnaire 132 0.9 (0.7, 1.0) 2.6 (2.2, 3.1) 9
RECRUITER
RCT Fleissig Standard 96 73.8 (66.3, 81.4) 47 Doctor aware of patient's responses 109 80.7 (74.1, 87.4) 53 205
QRCT Miller Senior investigator 28 17.3 (11.5, 23.1) 17.3 (11.5, 23.1) 56 Research assistance 22 11.9 (7.2, 16.6) 11.9 (7.2, 16.6) 44 50
PCS Gill Primary care physicians referral 101 6.6 (5.4, 7.9) 36.6 (30.9, 42,3) 54 Research staff recruitment 87 8.5 (6.8, 10.2) 35.2 (29.3, 41.2) 46 188
RCS Isaacman2 Investigator physician 73 84.9 (77.3, 92.5) 84.9 (77.3, 92.5) 46 Research nurse 84 79.2 (71.5, 87.0) 79.2 (71.5, 87.0) 54 157
BAS Isaacman1 Physician investigator 40 14.2 (10.1, 18.3) 80.0 (68.9, 91.1) 80.0 (68.9, 91.1) 24 Physician investigator + research nurse 126 49.8 (43.6, 56.0) 83.4 (77.5, 89.4) 83.4 (77.5, 89.4) 76 166
PCS Wadland1 Semi-rural private family practice 58 10.1 (7.6, 12.5) 62 Academic university practice 36 2.1 (1.4, 2.8) 38 94
RCS Wright* Private solo practices 13791 36 Private group practices 8568 22 38523
Health maintenance organisations 1591 4 Community health centers 3641 9
University academic medical centers 3865 10 Department of veteran affairs medical centers 7067 18
Carew1* Radionuclide lab 955 59 Cardiac catheter lab 296 18 1629
Echocardiogram lab 230 14 Other referral 148 9
Carew2* Radionuclide lab 1151 46 Cardiac catheter lab 676 27 2477
Echocardiogram lab 350 14 Other referral 300 12
CONSENT
RCT Myles One sided informed consent 84 55.6 (47.7, 63.6) 20 429
Prerandomised to experimental drug 90 53.3 (45.7, 60.8) 21 Prerandomised to standard drug 79 53.0 (45.0, 61.0) 18
One sided physician modified informed consent 91 60.7 (52.8, 68.5) 21 One sided patient modified informed consent 85 56.7 (48.7, 64.6) 20 429
Gallo One sided informed consent 521 83.8 (80.9,. 86.7) 32 Two sided informed consent 304 80.9 (76.9, 84.8) 19 1623
Prerandomised to standard drug 156 50.8 (45.2, 56.4) 10 Prerandomised to experimental drug 642 87.9 (85.6, 90.3) 40
* Consent rates cannot be calculated. RCT=randomised controlled trial,    QRCT=quasi-randomised controlled trial,    PCS=prospective cohort study,    RCS=retrospective cohort study,    BAS=before after study
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Table 3.6: Comparing consent rates and proportions for studies evaluating variations of one category of recruitment method
AUTHOR METHOD Exposed
Consent Rate %
% Recruited METHOD Exposed
Consent Rate %
% Recruited METHOD Exposed
Consent Rate
Proportion
Recruited
Total
Enrolled
FRAMING
Wragg Providing estimates of
effect
30.8 low 36 low Emphasising uncertainty 58.3 high 64 high 22
Leader Emphasising data
gathering
0.9 low 7 low Focusing on early diagnosis 9.7 high 93 high 60
INFORMATION PRESENTATION
Aaronson Control 86.7 high 53 high Additional nurse 75.6 low 47 low 146
Wadland2 Control 47.2 NS 48 low Additional study coordinator 52.9 NS 52 high 52
Llewellyn-
Thomas
Tape recording 42.0 low 40.4 low Interactive computer program 62 high 59.6 high 83
Daily newspaper 51 high Weekly newspaper 17 low TV news 16 lowArnold
Community TV 1 low Radio 14 low
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MAILING
Mailing with no incentive 27.4 low 18 low Prepaid $2 cash 40.3 high 27 high $15 cash contingent on
response
43.0 high 29 highMartinson
$200 prize draw 37.8 high 25 high
1560
Valanis2 Full recruitment packet 2.3 NS 46 low Advanced postcard 2.7 NS 54 high 563
First class postage &
letter from trial
investigator
2.0 interme
diate
25 high First class postage & letter
from medical director
1.2 low 9 low First class non profit
postage & letter from trial
investigator
2.5 high 20 high 1502Valanis1
First class non profit
postage & letter from
medical director
1.1 low 19 high First class postage of
questionnaire
1.0 low 19 high Bulk rate postage of
questionnaire
0.9 low 9 low 1502
RECRUITER DEPENDENT FACTORS
Fleissig Standard 73.8 NS 47 low Doctor aware of patient's
responses
80.7 NS 53 high 205
Miller Senior investigator 56 high Research assistance 44 low 50
Gill Primary care physicians
referral
54 high Research staff recruitment 46 low 188
Isaacman2 Investigator physician 46 low Research nurse 54 high 157
Wadland1 Semi-rural private family
practice
62 high Academic university practice 38 low 94
Private solo practices 36 high Private group practices 22 high Health maintenance
organisations
4 lowWright
Community health centers 9 low University academic medical
centres
10 low Department of veteran affairs medical centres 18 high
38523
Radionuclide lab 59 high Cardiac catheter lab 18 low Echocardiogram lab 14 lowCarew1
Other referral 9 low
1629
Radionuclide lab 46 high Cardiac catheter lab 27 high Echocardiogram lab 14 lowCarew2
Other referral 12 low
2477
Isaacman1 Physician investigator 14.2 low 24 low Physician investigator &
research nurse
49.8 high 76 high 166
METHOD OF INFORMED CONSENT
One sided informed
consent
55.6 NS 20 same Prerandomised to
experimental drug
53.3 NS 21 same Prerandomised to standard
drug
53.0 NS 18 lowMyles
One sided physician
modified informed
consent
60.7 NS 21 same One sided patient modified
informed consent
56.7 NS 20 same
429
One sided informed
consent
83.8 high 32 high Prerandomised to
experimental drug
87.9 high 40 high Prerandomised to standard
drug
50.8 low 10 lowGallo
Two sided informed
consent
80.9 high 19 low
1623
Exposed consent rate relative to each other (if 95% CI does not cross, consent rates considered significantly different). NS = not significant
Proportion of study recruited by each method: Observed proportion compared with expected proportion. "High" if proportion > 1/number of strategies used in the study, "low" if proportion < 1/number of strategies used in the study.
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3.3.6 Recruitment cost per participant
Recruitment costs for some or all methods of recruitment used were described in 20
studies (Table 3.7). The stated cost per participant enrolled ranged from US $0 for some
personal referrals to $1108.00 for bus advertisements. When subcategories were
combined, the average costs were US $113.26 for mailing, $164.69 for media, $242.98
for personal methods and $452.99 for community approach.
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Table 3.7: Recruitment costs per participant enrolled by method of recruitment
AUTHOR PERSONAL COMMUNITY MAILING MEDIA
No incentives 18.45
$2 cash (prepaid) 17.52
$15 cash (on response) 35.68
Martinson
$200 prize draw 18.42
Senior investigator $78.48Miller
Research assistant $50.28
Folmar Research staff $1,715.00 General community $1,152.00
HCP referral $868.00Gill
Research staff $764.00
Margitic (D) Research staff $80.00 Questionnaires $14.00
Margitic (S) Questionnaires $253.00 Mass mailing $58.00
Goodman Mass mailing 442.00
First class postage (letter from investigator) 83.00
Non profit postage (letter from investigator) 58.00
First class postage (letter from insurance medical director) 138.00
Non profit postage (letter from insurance medical director) 128.00
First class postage with mailer 169.00
Valanis1
Bulk rate postage with mailer 151.00
HCP referral $58.00 Presentation $108.00 Target mailing $114.00 combined media $84.00Adams
Research staff $142.00 Fliers $203.00
King Research staff $168.45 combined media $61.51
General community $42.54 Mass mailing $59.37Silagy
Target mailing $48.36
First class postage $188.12Tworoger
Bulk rate postage $131.98
Lewis (A) Mass mailing $103.00 combined media $33.00
Lewis (B) Mass mailing $144.00 combined media $207.00
Coleman Research staff $42.00 combined media $45.00
Whelton Mass mailing $127.00 Printed media $51.00
HCP referral $62.50 Presentation $906.25 Target mailing $294.33 combined media $37.00Anderson
Promoting to HCP $40.75 Posters and brochures $904.00
Moon1 HCP referral $75.00 combined media $57.48
Moon2 HCP referral $75.00 Target mailing $36.35 combined media $431.02
HCP referral $0.00 Fliers $365.00 combined media $999.00
Posters and brochures $196.00
Piotrowski
Bus ads $1,108.00
HCP referral $77.00 Worksite $82.00 Mass mailing $135.00 combined media $54.00Bjornson-
Benson General community $670.00
HCP referral $0.00 Posters and brochures $338.00 TV, radio $28.00Burns
Printed media $52.90
Average
costs
Personal $242.98 Community $452.99 Mailing $113.26 Media $164.69
HCP = health care provider, WOM = word of mouth, Cost calculated in US dollars
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Figure 3.4: Forest plots of consent rates comparing different categories of
recruitment methods
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3.4 Discussion
This systematic review of strategies for increasing recruitment to RCTs has
identified 50 publications examining how more than 4 million potential
participants were approached to RCTs participation.
There were 87 different recruitment strategies evaluated which were grouped into
5 major categories including personal methods, community approach, mailing,
media and other (such as styles of informed consent, framing of recruitment
information, methods of information presentation and comparison of recruiter
dependent variables).
The primary outcome of interest was the consent rate. Although the exposed
consent rate most closely reflects the effectiveness of a recruitment strategy,
exposure is often difficult to measure (e.g. media), and can be misreported. The
small number of studies describing exposure consent rates limits the application
of our findings. The responder consent rate was easier to measure, and was
more often reported. The assessed consent rate measured eligibility rather than
potential participants’ willingness to enrol in a trial, and therefore is the least
useful consent rate for assessing the effectiveness of recruitment strategies.
The study types of included publications ranged from RCTs to before after
studies, with poor methodological quality identified in most studies. This limited
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generalisability of the results, with uncertainty remaining about the relative
effectiveness of the different methods.
When evaluating consent rates in studies comparing different categories of
recruitment, a trend for personal methods being more effective than impersonal
methods such as mailing and media was demonstrated, with health care provider
referrals having the highest consent rate. This is not surprising, as the influence
of doctors’ recommendations for trial participation has been reported in other
studies (50;51). However, not all strategies within a category of recruitment
method are the same. For example, health care provider referrals generally have
higher consent rates than other personal methods of recruitment such as
research staff recruitment, and community presentations are more effective than
general community methods such as fliers and brochures. Even within a category
of recruitment method, the trend again favours a more personal approach.
When evaluating consent rates for the studies comparing different variations of
recruitment within one category, several strategies were identified as effective.
The use of monetary incentives is effective, but whether this is ethical
(particularly for children) has been questioned by many (122;123). The
suggestion that  framing recruitment information (e.g. by emphasising
uncertainty) may improve recruitment is very exciting and warrants further
research. This strategy has implications for researchers, as it attracts little
additional cost and can be incorporated into other methods of recruitment.
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However, the use of framing by emphasising uncertainty when inviting potential
participants for trial participation without exploring the values of the individual or
informing them of prior probabilities, was thought by some to be inadequate and
misleading (144). Other effective methods such as the use of an interactive
computer program for potential participants to find out more about the trial and
informing recruiting doctors of patients’ preferences regarding treatment and trial
participation increase involvement of potential participants in the decision making
process. These may be considered ideal methods.
The difference between consent rates and absolute number enrolled by each
method suggests that both need to be considered in cost calculations. There is a
trade-off between increasing exposure of potential participants to trial information
and using methods with higher consent rates. Although health care provider
referrals have the highest consent rates, the small number of potential
participants who are exposed to trial information by this method compared with
other methods such as mailing and media limits its application. It may therefore
be faster and more cost effective to recruit by mailing of trial information to
potential participants than by health care provider referral.
The cost of recruitment by recruitment method was not measured in the same
way between studies because infrastructure and other costs were not
consistently included (e.g. the reported cost per participant recruited by health
care provide referrals ranged from $0 to $868), making comparisons difficult.
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However, identification of ineffective methods of recruitment (such as bus
advertisements, community presentations, community fliers etc) should steer
researchers to abandon (or at least question) these methods.
3.5 Conclusions
How do researchers decide which methods to employ when recruiting
participants for RCTs? Consideration must be given to exposure of potential
participants to trial information, the consent rates of the recruitment methods
used and costs of recruitment. Personalised referral by healthcare providers had
the highest consent rate but mailing of trial information to potential participants
was the most cost effective method overall.
Success of future trials depends on using ethical and cost effective means of
recruiting study participants. Future research on framing of recruitment
information, informing doctors of patients’ preferences regarding treatment and
trial participation and interactive methods which allow potential participants
opportunity to find out about trials is needed.
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Chapter 4 – Paediatricians’ attitudes to children’s participation
in randomised controlled trials (focus group research)
4.1 Introduction
Doctors’ reluctance to enrol patients is one of the most significant obstacles to
trial success (47-49) as patients will rarely participate unless actively
recommended to do so by their physician (51;145). This reluctance is considered
a foreseeable consequence of the attempt to integrate the conflicting roles of
clinician and researcher in RCTs (46). Taylor suggests the participation of
doctors in trials can be predicted by their primary affiliation as either “clinicians”
(with primary allegiance to the individual patient), or “researchers” (with primary
allegiance to the community to generate scientific data) (46;48).
The RCT recruitment process is a relatively new area of inquiry, with previous
research mostly confined to studies of adult recruitment (41;52;72;82;146;147).
Recruitment issues in paediatric and adult RCTs are thought to be quite different
(75). With the exception of paediatric oncology, children’s recruitment to trials
was thought to be more difficult (148). Although there are some studies that
address paediatric trial recruitment (44;86;89;149;150), most address parental
attitudes to trials (65;73;87;88;91;120;151). Little is known about paediatricians’
attitudes to trials (83). With the increasing recognition of the need to include
children as participants in RCTs (14;22;24;29), it has become even more
important to explore barriers to children’s participation in trials. The aim of this
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study was to examine paediatricians’ attitudes and identify possible physician-
related barriers to children’s participation in RCTs.
4.2 Methods
4.2.1 Participants
In Australia, primary care paediatricians and trainees refer children to RCTs, who
are then enrolled by the trial investigators. These paediatricians do not generally
receive any reward for recruiting patients, apart from departmental approval and
a sense of personal achievement. Clinical pharmacologists, while playing an
important role in trial conduct, do not recruit patients to trials.
Paediatricians and trainees from The Children’s Hospital at Westmead (CHW), a
350-bed paediatric tertiary teaching hospital in Sydney, were invited to participate
in the study. Purposive sampling was employed to ensure that all groups with
unique views were represented (152;153). Participating doctors varied in
occupation, experience, research activity, age, gender, ethnicity and parenthood
experience (see Table 4.1). Unavailability at the scheduled time was the main
reason for non-participation in the study.
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Table 4.1: Characteristics of participating paediatricians
Characteristics No. (%)
Sex
     Male 13   (62)
     Female 8     (38)
Age
     25 – 34 years 4     (19)
     35 – 44 years 7     (33)
     45 – 54 years 5     (24)
     55 – 65 years 5     (24)
Position
     Admitting medical officers with private practice 4     (19)
     Staff specialists – general paediatrics 2     (10)
     Staff specialists - subspecialties 9     (43)
     Trainee paediatricians 5     (24)
     Career medical officer 1     ( 5)
Length of medical  practice
     Less than 10 years 4     (19)
     11 – 20 years 7     (33)
     21 – 30 years 5     (24)
     31 – 40 years 5     (24)
Research experience
     Previously conducted research
     (“Research-clinician”)
10   (48)
     Limited research experience
     (“Nonresearch-clinician”)
6     (29)
     Trainees with research experience 3     (14)
     Trainees with no research experience 2     (10)
Ethnic origin
     Australian 14   (67)
     Asian 3     (14)
     Eastern European 2     (10)
     Other Caucasian 2     (10)
Parenting experience
     No children 8    (38)
     Have children 13   (62)
Age of children
     Toddler (<5 years) 1     ( 5)
     School age (5-18 years) 7     (33)
     Adult (>18 years) 8     (38)
(Note: children may be in more than age group)
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4.2.2 Focus groups
Verbal consent was obtained from each participant. Semi-structured group
discussions were conducted using an open-ended questioning approach. A
“prompts sheet” for the focus group discussion was designed to cover the topic in
adequate depth and in a consistent manner between groups (Appendix C). To
ensure free discussion and interaction, consultant paediatricians and trainees
attended separate groups. All participants completed a sociodemograpic
questionnaire (Appendix D). Because the researcher was known to most of the
participants, a professional facilitator unknown to them who is skilled at using
probing techniques and pacing the group and who was thought to possibly be
less threatening, conducted the discussions, with the researcher observing and
taking field notes. Each session lasted 60 minutes and was audiotaped.
Recruitment ceased when informational redundancy was reached (when no
further information was gained), after 4 focus groups involving 21 participants.
4.2.3 Analysis
The audiotapes were transcribed and checked against field notes for accuracy
and inclusion of non-verbal details. The transcribed audiotape data were
organised and coded into discrete categories using the constant comparative
method where each item is compared with the rest of the data to establish
analytical categories that are mutually exclusive (153;154) and then further
examined to identify emergent over-arching themes (152). Analyses of
differences in responses between participants from the various occupations,
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experience, research activity, age, gender, ethnicity and parenthood experience
subgroups groups were undertaken. All participants had an opportunity to read
and comment on the results.
4.3 Results
Participant views were organised into two broad themes encompassing factors
thought to influence parents’ and paediatricians’ attitudes to children’s trial
participation (Figure 4.1). As research experience differentiated participant
responses, these differences are highlighted in the results presented below.
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Figure 4.1: Paediatricians’ thoughts on factors that influenced children’s
participation in randomised controlled trials
4.3.1 Paediatricians’ beliefs about parental attitudes
4.3.1.1 Parents’ beliefs and knowledge
Most paediatricians believed that there is poor community awareness of RCTs,
with confusion about equipoise (a state of collective uncertainty about the relative
merits of alternative treatments), placebo usage (to demonstrate the real effects
Paediatricians’ thoughts on factors
that influenced children’s
participation in RCTs
Factors influencing parents’
attitudes:
1. Parents’ beliefs
2. Parental attributes
3. The child’s condition
Decision for participation in RCT
Gains and benefits
1. Personal benefits
2. Convenience
3. Scientific advancement
Factors influencing
paediatricians’ attitudes:
1. Paediatricians’ beliefs
2. Relationship with
investigators
Risks and harms
1. Potential harms
2. Lack of resources/
inconvenience
3. Risk to doctor-patient
relationship
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of treatment) and random allocation (so that any differences at the end of a study
will be attributable to the treatment alone).
“I also think, yeah, people just don’t know much about trials.  I don’t think
its something that’s generally out there, in the community.”
“But when you got to the bit about ”I can’t tell you which one it will be, it’s
determined by chance,” they really, found that a really big sticking point …
that they couldn’t choose which treatment their baby was going to get.”
“Even if they actually have heard of the word “placebo”, I think they
haven’t thought it through to think what it really means.  That it really
means, theoretically, no treatment.”
“.. they find it (randomisation) uncomfortable”
They speculated that most parents did not understand equipoise, believing newer
treatments were better than old, more treatment was better than less, and any
treatment was better than none. Paediatricians observed greater difficulty
recruiting for placebo-controlled trials compared with trials of active treatments.
“..they want the drug or the substance or the treatment.  They don’t want
to have any risk of being put into a non-treatment group and I think that
that really is a general rule.”
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“(regarding trials of active treatments) I think that is often easier than
treatment or no treatment, depending on the study.”
Participants also observed that consumer groups promoted these attitudes,
demanding new treatments without evaluation
“..they didn’t have good evidence for it.  But as soon as some new thing is
suggested, they want it and then they don’t want trials”.
“..the media influences the patient or the public knowledge about the
trials.”
However, some “research-clinicians” sensed increasing community awareness
and acceptance of RCTs.
“I think people are becoming increasingly aware of it and I guess, certainly
when you talk to them about these sorts of studies, they can understand
the rationale..”
Paediatricians believed their opinions influenced parents’ decisions for trial
participation. They also thought parents were more willing to participate in trials
they considered important because of media promotion or doctors’
recommendations.
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“..if their doctor recommends it and someone that they respect talks to
them about it, that they will consider it… might, under those circumstances
participate”
“If it’s something like immunisation, a lot of people see the worthwhileness
of that, I think community awareness is good enough for immunisation,
people do see the advantage”.
Participants sensed fear and mistrust of research by many parents. This anxiety
was thought to be exaggerated in paediatric trials because of parental
protectiveness and apprehension regarding experimentation on children (treating
them as  “guinea pigs”). Some felt parents may respond differently about
participation in trials themselves.
“I think people who don’t do research, find research a bit scary, a bit
frightening..”
“..a  parent’s job … is to get the best possible care for their child..”
“..you’ve got to convince parents and nobody particularly wants to make
their child a guinea pig.”
“It’s different when you’re consenting for yourself.”
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4.3.1.2 Parents’ attributes
The paediatricians identified a spectrum of parents ranging from those willing to
participate in any trials to those always against participation. Likely participants
were thought to be middle class, educated, Internet information seekers who
were “..‘PLOs’ (people like ourselves)”.  However, some “research-clinicians”
refuted this.  Paediatricians admitted preferentially approaching “PLOs” because
of easier communication and likelihood of trial participation.
“..inherently you get a biased sample, because there are psychologically
two types of parents, one who’ll say I’ll be in a trial and one who’ll say I
wouldn’t be in a trial for quids.”
“..I use PLO’s (people like ourselves)  to mean educated…this is the
volunteer effect, educated, rather middle classed, in general… those
people are much easier to interact with, because we have ways of
communicating, that happen naturally, without us even trying and we
relate to them in all sorts of ways, of which we are unaware.”
“ I think you do sniff out middle class families because you think they’re
likely to say, yes… they’re more likely to understand, you have to put less
effort into convincing them.”
“I guess you always feel better about well-educated parents as well…you
feel that they will understand what’s involved.”
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Those from low socio-economic, non-English speaking or Aboriginal
backgrounds were thought less likely to participate, although this was also
refuted by some “research-clinicians”. Other culturally related factors such as
non-attendance at follow-up and particular treatment preferences were also
thought to impede participation.
(people less likely to participate are) “..low socioeconomic status,
Aboriginal background”
“A language barrier is always another thing.  If you’ve got parents who
don’t speak particularly good English, and you haven’t got an interpreter
around, it’s nigh on impossible to do recruiting.”
“I have also had lots of good experiences with people who are obviously
not well educated but who are very willing to participate in the trial and
who seem to understand the basics of it.”
Many paediatricians believed the child’s doctor should decide which patients to
approach about trials because they judged some parents incapable of coping
with the demands of participation or unable to give informed consent because of
language barriers or level of distress.
“I think that’s up to the individual physician to who is referring or being
asked to refer patients to trial.”
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 “I wouldn’t ask anyone who was obviously upset or was obviously very
anxious about their child. It depends..”
“..you meet families who would believe that they lack sufficient resources
to get a bus ticket.  They might be extremely pleasant people, but you
think, I’m going to ask them to this, this, this and this ….. and it just won’t
work..”
“I don’t think they would cope with this study.”
4.3.1.3 The child’s condition
Patients with a poor prognosis were thought to be less likely to participate in
trials. In particular, parents desperate for hope might refuse participation in
placebo-controlled trials.
 “..this desperate group…see the proposed therapy as potentially
lifesaving, and the proposed alternative, as doing nothing”.
“I think it brings up the point that the more desperate the group, the harder
it is..”
However, parents exposed to disciplines with a “research culture” were thought
to be more willing to participate in trials. Some “research-clinicians” thought
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parents with chronically ill children might view trial participation as another
treatment option, but some were considered poor trial candidates because they
were unable to alter their entrenched response to illness.
“..in oncology, the whole philosophy of the place is that the treatment of
children with cancers is an ongoing clinical trial… and parents are very
happy to go into trials on that basis because the philosophy is completely
different.”
 “..and usually these people are quite keen to participate in things … the
condition is such that they are sort of looking for anything, and I actually
like the idea of there being another facet to their management”
“..some patients who have particularly chronic disease, who have got into
a certain psychosocial situation where there is no point in trying to modify,
or getting those people to do something different..”
4.3.2 Paediatricians’ attitudes
4.3.2.1 Paediatricians’ beliefs
Most paediatricians acknowledged the importance of paediatric RCTs because of
children’s particular health issues.
“..a lot of the conditions we treat in childhood are different to adults and as
well as obviously children  having different responses, to also dealing with
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different sorts of diseases that really need their own sort of  randomised
clinical trials in some situations.”
“..they have health issues that are peculiar to them and you can’t just do it
as a flog off from adult research.”
“Nonresearch-clinicians” preferred safety-testing treatments on adults first
“..so I quite like a little bit of early trialing in adults before you actually then
transfer to children”, whereas “research-clinicians” perceived this as “..just
depriving children of potentially useful therapy”.
“Well that whole process before you hear about these new drugs, and we
know from past experience we may not get them for 5 or 7 years,
something like that.  Whereas, if the drug’s got promise, we may want to
use it now, not in 5 years time.”
Many paediatricians expressed discomfort about placebo usage and
randomisation, particularly for terminally ill patients:
“..but certainly up in departments where I work, there is a bit of a move
against randomised controlled trials.  Why do we need to do them anyway.
Is it ethical to randomised someone?”
“..I am always very sad for them when they get randomised to the control
group… you want them to be in one of the other arms.”
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“..a treatment that is potentially life-saving… a treatment of last resort…
You can’t ethically randomise that, can you?  Because, by the time you
have got to the entry point, you’ve said there is no useful treatment.”
“Research-clinicians”, aware of published data on superior outcomes of all trial
participants, perceived “inclusion benefits” for all participants whereas
“Nonresearch-clinicians” saw no benefits for those on placebo.
“It’s been well documented… there have been nice studies which show
that up to 40% placebo effect with treatment and that probably is related to
the fact that they come in more regularly and are seen more regularly.
They are more aware of their disease.”
“..if the child’s going to be randomised into one or two streams, in that
situation, one would have a hunch that in certain circumstances it’s going
to be of no benefit whatsoever.”
All paediatricians favoured trials that they considered are clinically relevant.
Many, despite community equipoise, had personal preferences about treatment
options, which, although not outwardly acknowledged, were thought to subtly
influence parents’ decisions about participation. Some were reluctant to test
current therapies by RCTs, preferring to rely on anecdotal evidence. However,
most claimed they trusted ethics committees’ approval of trials.
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“..looking at a question that has a clinical implication: …questions that are
purely scientific are necessary but,: being a clinician, I am much more
interested in trials that look at the clinical application of what we do or how
we do it.  Or assessing what we are doing to see if actually it makes a
difference.”
“I think that it depends on if you agree with what they are doing, to start
with. If you’re not comfortable with the original treatment, it is very hard to
put your patient through that and then send them onto a trial that
somebody else is dictated.”
“If you’re uncomfortable about not treating someone, it means you believe
there is a difference.”
“If they read from the person running the trial, that the person running the
trial believes that the treatment works, and now there’s a chance that you
won’t get the treatment, they won’t go on that …she thinks this thing ought
to work.  Well, I’ll just go and get it, thank you.”
“..they might not have that evidence based view, they might feel that what
I do now is adequate, I’ve done it before with kids, it works..”
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“..if the thing’s been passed by the Ethic’s Committee and that’s….some
fairly prestigious scientists, well it’s good enough for me.”
4.3.2.2 The paediatrician’s relationship with investigators
Paediatricians acknowledged their relationship with investigators affected
recruitment.
“..but it does contaminate the culture of involvement in studies, the next
time you see a request to be involved in a study, you get contaminated by
your last experience..”
Some acknowledged rivalry between research groups, admitting referring
patients was often “..not a matter of suitability (but)…a matter of competition”.
Investigators’ communication with paediatricians was generally considered poor,
with lack of consultation and inadequate feedback about recruitment closure, trial
progress and patient follow-up. Trial unfamiliarity was identified as a particular
problem in departments with high staff turnover because of poor communication.
All paediatricians agreed on the importance of a trial contact who was available,
enthusiastic and “..recognised by everybody as being competent and skilful, but
also isn’t a competitor”. Lack of consultation and support by investigators and
lack of ownership were experienced by many, especially “trainees” who resented
the expectation of their involvement. Enlisting the support of key gatekeepers
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(community paediatricians, senior consultants, nursing staff) as well as staff
involved in recruitment who derive little benefit from participation was considered
essential.
“..we don’t believe we’re engaged enough in the functioning of this
hospital as visitors … maybe there’s some merit in formulating a study to
engage one of us on the study group to give some ideas as to how best
they may be recruited in private practice.”
“no-one has actually bothered to explain to me what the randomised
control trial is about, so I don’t feel like I have any ownership of it..”
“..Particularly when you’ve got such a flux in staff, and you’ve got so many
people coming and going, it is hard to get communication… you’ve got
people coming and they might be here for a few weeks… don’t really hear
unless somebody really specifically goes round and educates them.”
“..quite effective if you have someone who is dedicated to it, in terms of,
not as much a single person whose job it is to do it, but in terms of
someone who wants to actually do it.  So, if it’s an enthusiastic person,
that gets the message across much more effectively.”
“So, you really have to have the local paediatricians on side, or they just
refuse.  They by-pass it completely.”
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4.3.3 Gains and benefits
4.3.3.1 Personal benefits
Paediatricians speculated that parents who perceived personal benefits for their
child were more likely to participate in trials. These benefits include thorough
follow up, special attention, access to information about the underlying condition
and to extra resources including new treatments not routinely unavailable.
“Research-clinicians” also thought “emotional bribes” were used, such as giving
participants priority in accessing restricted treatments at the completion of trials.
“I think for the parents and children participating… it’s that feeling of being
special and being looked after, as well as obviously the hope that they will
derive some benefit from participating which they wouldn’t, otherwise,
have access to.”
“..basically, they felt they were special, that they got a lot of attention and
that … things were being looked after very well”
“..it’s not available …But it will be costly, when it is available, and they’re
kind of, they’re in on the first run..”
“..they would get priority as far as clinical appointments were concerned
afterwards… It’s not really a bribe, it’s kind of a bribe,  it’s an emotional
bribe I suppose.”
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“Research-clinicians” perceived most professional gains from trial participation,
and “Nonresearch-clinicians” the least.  “Research-clinicians” recognised the
discipline of adhering to a research protocol improved their clinical practice, and
thought participation was “..a way of propagating (appropriate management) and
actually adjusts clinical practice”.  They acknowledged that “..those skills may
actually go on and live longer than the outcome.”  They also sought professional
recognition and enjoyed increased interaction with specialists from different fields
as a result of participation.  “Trainees” enjoyed learning about conducting
research. “Nonresearch-clinicians” perceived few professional gains.
“..I think that’s very important if you’re going to put some time and effort
into something and you want that time and effort to be recognised.  I don’t
mean you must win a medal but I mean, you got to…it’s got to appear to
you that you’re being appropriately acknowledged - if you have made a
major contribution, that you are an author, if you have simply provided
some material, that you’re acknowledged at the end of the article.”
“..I have sometimes learnt a lot by the process of participating.  Either
running one or  actually being a participant.”
“Sometimes conducting a clinical trial is an extremely useful way of getting
a whole bunch of people who don’t ordinarily work in the same direction,
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so it can be a very powerful tool, …  of harnessing different groups of
people to a common purpose.”
(Trainee) “…I found that it’s interesting to see how they do things, even
though I’ve not really been involved other than trying to collect kids as they
come through.  It just gives you a little bit of an idea about how people go
about conducting research and the kind of hassles that they get.”
“And then the next question is ‘what’s in it for me?”
4.3.3.2 Convenience
“Research-clinicians” noted that recruitment is enhanced by making participation
more convenient for families by offering home visits, travel cost reimbursements
and provision of free medication. However, all participants objected ethically to
offering monetary incentives for children.
“..was really very successful in achieving a truly randomised sample,
because a) we went to them, and b)  we only went once.”
“One thing which was far more successful than we ever thought was going
to be, was we just offered to pay for travel costs to and from the hospital
which for some of our families, in fact made the difference between I’m
sure …coming and not coming.”
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“..I used to say “ well otherwise it would cost a lot of money, you will get it
for free..”
“..I know they pay a lot of the adults to actually take part in it.  I don’t
actually think that’s a great idea for the childhood studies…I know their
parents are supposed to be their best advocates and so on, but I think if
you say “we’re going to pay you to have your child take part in this study”,
I just don’t – I don’t find that right.”
Paediatricians preferred trials with easy referral, where they only had to identify
eligible patients, or trials that decreased their workload, where routine
investigations were organised by the research team.
“I think one of the important things from my point of view, if I’m very
honest, is a combination of how common is the condition and how much is
involved in my referring to that trial. So, if it’s very easy to refer to the
Trial…because it’s so easy -it’s easy. If it gets to be harder…. and
requires more of my time, if it’s a fairly common condition, I’ll let myself off
every second time, because I just frankly haven’t got the time to go to the
trouble that’s involved”
“..trial was actually doing the follow-up investigations you were going to
have organise anyway.  So it actually took some work away from us,
which was really good, because it’s fiddly trying to make all those
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appointments. ..And that’s what was quite attractive about it, there was
actually incentive there to do it.”
Referring patients for trials at the time of the consultation was considered more
convenient for consultant paediatricians. However, “trainees” responsible for
overseeing treatments disliked trials where decisions for enrolment were made at
presentation, because it increased their workload.
“The closer the recruiting is to the diagnosis (the better)…Lag factor is
bad.”
4.3.3.3 Scientific advancement and future patient benefit
All paediatricians acknowledged scientific advancement and future patient
benefits as important altruistic motives for parents and doctors. Many derived
satisfaction from contributing to scientific evidence, which some believed should
be a community responsibility, even if there were no immediate benefits. Others
were more concerned with personal benefits for their patients.
“There is a satisfaction to knowing that you’re not just doing it, you’re
doing it because you’ve shown or you help show, that it is some sort of
positive benefit to the patient. That is what I would find most satisfying.
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4.3.4 Risks or harms
4.3.4.1 Potential harms
Paediatricians were concerned about the potential side effects of the treatments
being tested. Although acknowledged as unlikely, many had difficulty explaining
these to parents. “Research-clinicians” were less willing to expose patients to
potential side effects in trials requiring large sample sizes designed to detect a
small treatment effect.
“..side effects of drugs is another one, if we’re involved in certain drug
trials, you know there is usually long lists of potential side effects that you
have to go through and that can be a bit difficult. I mean, one knows that
these are almost certainly not going to apply but because this is a trial
situation you’ve actually got to be very careful about explaining, you’ve got
to get consent on each occasion, you know, it can be difficult..”
“Although the potential harm may not be that great. That you would have
to treat so many of them to get any benefit.  That’s a bit of concern.”
4.3.4.2 Inconvenience/ lack of resources
Identified patient inconveniences included additional investigations, follow-up
visits, travelling and additional costs. Most paediatricians disliked trials requiring
unpleasant non-routine procedures such as blood tests “..where it wouldn’t
normally have been done, it’s something that you feel a bit hesitant about ..”.
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Time constraint was a major obstacle to trial involvement for all participants. Most
“Nonresearch-clinicians” resented the extra demands of explaining about trials
and data collecting. “Research-clinicians” blamed lack of time for suboptimal
recruitment efforts.
“..but all studies involve a lot of time and a lot of paperwork, huge amounts
of paperwork, normally.”
“I think that as a clinician doing trials, you find that it (ie recruiting for trials)
is  an additional work load that you don’t have time for… time is a huge
factor, and if you had more time you could spend it actively recruiting and
being on the floor, or being in the focus and around and accessible and
finding people and writing letters to everybody whose involved, saying
what you’re doing and spending a lot more time communicating and
making sure everyone knows what is happening and where they’re up to
and, you know, the people in the trials as well as those people who are
involved in their care.”
Inadequate funding and resources were also considered hindrances to trial
participation. Although pharmaceutical trials are believed to be better funded,
many “research-clinicians” resented the extra administrative demands of
pharmaceutical companies, acknowledging a conflict of interest between
requirements for product registration and information for clinicians using those
products.
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“..the money is always horrendously underdone.  It’s the difference
between being able to do a study, being that it be under-funded, versus
not being able to do it because of the funding issue..”
“..I think there’s a difference between trials, studies that you’ve initiated
yourself, or have come out of good institutions versus ones that a
particular industry group has asked you to conduct because they need
that information for registration for a drug.  …there are differences there in
terms of how much the agenda is driven by an outside group versus
driven by you.”
4.3.4.3 Risk to the doctor-patient relationship/ quality of care
Some participants were concerned about their patients’ quality of care under the
research team, fearing that research would take priority over patients’ needs.
Others thought trial participation may threaten the doctor-patient relationship if
patients formed a bond with the research team. The potential loss of patients and
the resulting economic effects for paediatricians in private practice when referring
to trials was a serious concern.
“..for some of the patients, the people doing the study are really interested
in doing the study rather than managing the patient, and whereas the
patient sometimes falls between the cracks… we have moved away a bit
from the usual person because they’re doing these other things with these
other people …won’t take on all of their care..”
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“If you feel that it impinges on your ability to continue your relationship with
your patient, then you would think twice about subjecting them, your
patient, to that risk.”
“..where we can have difficulty finding patients we can hang on to… is that
the study group, snavell up our patients and take over..”
Many resented the imposition of trial protocols on their style of practice. Most
disliked directly approaching parents for trial participation and felt “rejected” by
parents who declined participation. Some were uncomfortable expressing
uncertainty, fearing mistrust by parents who expected doctors to know all the
answers. Many regarded their role as being the families’ advocates, feeling
obligated to protect families from excessive invasion by investigators.
“..If you were doing an RCT, for example, that will actually impose a format
on you that may not be part of your normal style… That can actually
impinge a bit, if you look at a protocol, and you think ‘Oh, gee, I’m going to
feel very uncomfortable in the way… this doesn’t suit my style’ ”
“No-one likes rejection..”
“It’s not part of their culture…, that we are still carrying on research.
There’s very much still an expectation that we do have all the answers.
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And, to say that we don’t actually know the answer and this is why we’re
doing this, I think freshly shatters that expectation, so then they don’t
particularly trust you because you’ve just said you don’t know the
answer..”
“My concern, always with these trials, …is it going to be of benefit to the
individual child in the process, not looking at the group but the individual
child.”
“I guess we also need to protect them against going into multiple trials,
because they are often being asked to either act as a control with a
different chronic disease or..”
4.3.5 Suggested improvements for the future
The participants made a number of suggestions for improving children’s
participation in RCTs. “Trainees”, acknowledging poor understanding of RCTs,
recommended education of doctors and medical students. Paediatricians
suggested increasing community awareness of trials through media promotion
and advertising in waiting rooms because “.. it makes it acceptable and
worthwhile”, preferring to respond to parents’ inquiries rather than “solicit”
participation.
“New graduate course, medical course, they are doing research, so
they’re learning about it much earlier on, and I think that probably doing it,
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is the only way… doing research is the only way you really get a feel for
why you’re doing it and you de-mystify it, you realize it’s got its own
problems and its own merits and its own barriers.”
“..generally raising community …, it would be nice if people were aware
that, yes, we do do these things, that we don’t have all the answers and
that we may ask you to think about participating, or ask you to think about
your child participating in this.  So, it’s not such a complete shock when
you suddenly mentioned the word research or study.”
Enlisting the support of paediatricians was recommended “..because the parents
will often ask (their paediatrician) … what do you think about this study… it’s
really up to the physician to say, well, I think it is appropriate or I don’t..”   Also,
improving investigators’ communication with paediatricians about trial progress
and findings, and involving paediatricians in the follow up of trial participants
were suggested.
“I wonder how many people who actually involve, or involve their children
in trials, actually get feedback at the end of the trial about the outcome.  I
wonder if that is actually a helpful thing as a process in terms of improving
people’s overall willingness to participate.”
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“You should build into it, that they (ie general paediatricians) are going to
follow them up and you do it as part of your consultation.  Otherwise, you
are not going to recruit your patients.”
Providing a trial contact would encourage paediatricians’ involvement by
minimising the extra work required for recruitment. “Research-clinicians”
suggested more “protected time” for research as another solution, as many
researchers in Australia do not have protected research time, with funded
research time often pressured by clinical commitments.
“And you are far more likely to refer them… If you had somebody that was
dedicated to going through all that extra work of convincing the parents
and getting the consent and explaining the trial, you’re more likely to do it
because you don’t have to spend that hour trying to convince them to do
it.”
“…we can all do with more time to allocate to clinical research.”
4.4 Discussion
This study has highlighted some attitudes and beliefs held by paediatricians that
have implications for researchers wanting to involve children and medical
educators who teach trial theory and practice. Paediatricians’ views about trials
involving children are complex. They must balance their own attitudes, what they
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believe to be the parents’ views, and their perception of the benefits and risks of
a specific trial, in the decision making process.
In general, the balance of perceived gains versus risks for paediatric RCTs
participation means that non-participation will be the outcome in many instances.
For many paediatricians the individual doctor-patient relationship is paramount
and RCTs tend to be seen as a hindrance and not a help. Participation in trials is
viewed as involving many negatives - more work, less money, sharing clinical
responsibilities with someone else, lack of control over interventions used, and a
threat to the trust of the patient in the doctor (who “does not know what is best”).
Paediatricians have a very strong commitment to the care of their individual
patients so that giving an intervention which the individual paediatrician thinks is
best may often outweigh the long-term, community-orientated benefits of
improving the health of children by appropriately evaluating interventions by
RCTs.
Does this study suggest any solutions? Reducing disadvantages of trial
participation and increasing advantages by making participation more convenient
for paediatricians and families and building better relationships between
investigators and clinicians based upon communication and trust may tip the
balance towards increased participation. Further, increasing community
awareness of trials in general and current, relevant trials in particular, coupled
with a favourable disposition to trials may encourage paediatricians in their
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support of RCTs involving children. This study also suggests that medical
educators may need  to use alternative strategies in communicating the
limitations of using healthcare interventions that have not been appropriately
studied (44).
Many of the findings were similar to those of studies involving adult physicians. It
is not surprising that paediatricians and physicians have similar attitudes to trial
participation.  Similarities include the influence doctors believe they have on their
patients’ decisions about trial participation (51) and the perception that patients
feared and mistrusted researchers (155).  They also considered patients from
non-English speaking backgrounds (156) or with poor prognosis (49) less willing
to participate in RCTs.  Interestingly, although paediatricians in this study
preferred approaching middle class patients, this group was considered more
difficult to approach in one adult study because they were likely to ask probing
questions (49). Paediatricians thought that parents exposed to disciplines with a
“research culture” such as oncology were more willing to participate in trials.
(46;49;157).
Paediatricians’ objection to offering monetary incentives for children, despite
acknowledging adult subjects are sometimes compensated, reflect the complex
issues of consent by proxy and the fear that parents may participate in trials for
personal gain instead of for the best interest of their child (13). Ironically,
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paediatricians had no objection to financial compensation for their own role in
trial recruitment.
In general, paediatricians appeared to have more “clinician” than “researcher”
attributes. The differences in response between participants with and without
previous research experience in this study confirmed the “researcher-clinician”
framework developed by Taylor et al (46;48). Do paediatricians develop a
“researcher” attitude as a result of their involvement in trials, or do they become
actively involved in trials because they have an interest in research?
Further research is needed to address the issues raised by this study and to
assess attitudes of parents who make the final decision for trial participation.
Are the results of this study generalizable to other places in Australia? The
participants of the focus group discussion were recruited from the Children’s
Hospital at Westmead, a 350 bed children’s hospital which is a tertiary referral
centre serving all children in the state of New South Wales in Australia. This
teaching hospital has a strong research focus in many subspecialties.
Paediatricians working here have a high exposure to research and  their
responses therefore cannot be generalised to paediatricians outside of that
setting. It is postulated that paediatricians outside of that setting are likely to be
less research focused, and the results of this study therefore highlight the plight
of paediatric clinical research in Australia.
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Can the results of this Australian study be applied to other countries? It is likely
that the general issues raised here are very applicable to other settings, with
some exceptions. In some settings the paediatrician may be both the primary
physician and the investigator on a trial so the discussion on paediatrician-
investigator relationships would not be relevant.  This is an extreme case of the
general principle which is that the weight given to each factor will vary across
countries and within any given country, but the factors shaping paediatricians’
attitudes to trials provided here are likely to be common to all. This requires
confirmation with similar studies carried out in other countries and settings.
4.5 Conclusion
Paediatricians’ attitudes to children’s participation in RCTs are likely to impact on
recruitment. Typically when recruitment targets are not met, changes are made
to the trial design and recruitment strategies. This study suggests that other
methods that address paediatricians’ concerns may also encourage participation.
This has implications for researchers working with children and for medical
educators. Educating paediatricians about RCTs and involving them in trials will
increasing their awareness of RCTs. Also closely scrutinizing each step of the
RCTs process to reduce disadvantages and increase advantages whenever
possible may tip the gains-hazard balance to favour participation.
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Chapter 5 – Australian paediatricians’ and adult physicians’
attitudes to randomised controlled trials (survey)
5.1 Introduction
Doctor-related factors have been cited as one of the primary reasons for poor
recruitment in clinical trials (47;51;145).  Barriers to trial participation for doctors
previously identified (41-43) include perceived conflicts between the roles of
clinician and scientist (46), time and financial constraints (61), lack of rewards
(46;53), dislike of loss of autonomy (62), problems with complying with protocols
(55), discomfort with randomisation (64), preference for particular treatments
(40;54-56;60), difficulty with ethics requirements and informed consent (51), and
concerns about patients’ wellbeing (40) and the doctor-patient relationship
(40;55;60;62;63). Previous studies on doctor barriers focused on recruitment for
oncology trials (54). However, little is known about paediatric trials (34;49;158).
The “Physician Oriented Profile” (POP) is a questionnaire designed to assess
doctors’ treatment philosophies. It has been used in several studies of cancer
specialists (46;48;49;64) to assess 5 indices of physician attitudes and behaviour
regarding RCTs: primary allegiance, professional activities, decision making
under uncertainty, perceived rewards and peer group influence (46;48). The
questionnaire provides individual scores, with mean scores ranging along a
continuum from the extremes of pure therapist (clinician-oriented) to pure
experimenter (research-oriented), which are predictive of doctors’ participation in
RCTs. Doctors with higher “POP” scores were considered to be more research-
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oriented, reported higher past accrual to trials and showed greater intention to
accrue in the future (64).
As little is known about Australian paediatricians’ attitudes to trial participation, a
modified “POP” was used in this study to compare responses between
paediatricians and adult physicians in Australia. Results were also compared with
UK/US data.
5.2 Methods
5.2.1 Participants
Five hundred doctors (250 adult physicians and 250 paediatricians) were
randomly selected by computer from the 7378 doctors registered with the Royal
Australasian College of Physicians and invited to participate (using RAND, a
computerised random number generator: Microsoft Excel 97). Doctors were sent
a questionnaire by mail and email together with a prepaid envelope, response
slip and explanatory letter. Non-responders were contacted at least twice to
minimise response bias.
5.2.2 The questionnaire
The questionnaire (Appendix E) is based on the “Physician Oriented Profile”
(POP), a previously validated questionnaire which assesses doctors’ treatment
philosophies and attitude to RCTs. It assesses 5 indices of physician attitudes
and behaviour regarding RCTs: primary allegiance, professional activities,
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decision making under uncertainty, perceived rewards and peer group influence
(46;48). The questionnaire provides individual scores along a continuum ranging
from the extremes of pure therapist (clinician oriented) to pure experimenter
(research oriented), which are predictive of doctors’ participation in RCTs.
The theoretical framework for the “Physician Oriented Profile” was based on
results from a preliminary study including in-depth observation and interviews of
42 breast cancer specialists (48). The “Physician Oriented Profile” has previously
been used in 4 separate studies:
· it was first applied as a 30-item typology to 484 breast cancer
specialists from 57 institutions in five countries between 1981 and
1985. The responses differentiated physicians with regard to their
attitude to participation in scientific research.
· A tailored version of the “POP” was applied to 101 physician-
investigators of the Collaborative Ocular Melanoma Study (COMS)
in the US and Canada (46).  This version consisted of 15
demographic questions, 45 binary option questions and 6 open
ended questions.
· The third study was a survey of the 1737 physician members of the
Eastern Cooperative Oncology Group (ECOG), where each
physician’s actual patient accrual was recorded. This confirmed that
doctors with higher “POP” scores were more research oriented,
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reported higher past accrual to trials and showed greater intention
to accrue in the future (64).
· The fourth study was conducted with 553 cancer specialists in the
UK using a 45-item questionnaire, and compared responses
between the UK and US studies.
The questions in this study are based on the wording from the fourth study.
The “POP” questionnaire was chosen in this setting because it qualitatively
measures doctors’ treatment philosophies and attitudes to RCTs and because
“POP” scores had been previously demonstrated to correlate with trial
participation. The application of this questionnaire on paediatricians and adult
physicians was limited by the original design, which was intended for cancer
specialists. Questions that were not relevant for the non-oncology context was
therefore excluded. This 44-item questionnaire was piloted by 10 doctors for
acceptability and content. After feedback from the pilot study, three questions
were reworded for the Australian context, and 2 questions were added. The final
questionnaire consisted of 11 items identifying demographic and practice details
of participants (which served as predictors of doctors’ treatment philosophies)
and 33 items assessing the doctor’s treatment philosophy and attitude to RCTs
using binary-option questions where possible.
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5.2.3 Analysis
When answers were divergent to given options, responses were matched to the
closest option given or were excluded if they did not match given options. “POP”
scores for doctors’ treatment philosophies were calculated using a similar
method to previous studies (48);(46;49;64) where each item was assigned a
score from 0 to 1, with pure “researcher or scientist” responses scoring 1 and
pure “clinician or therapist” responses scoring 0. The mean “POP” score was
derived by dividing the total “POP” score by the number of questions answered
and expressed as a number between 0 and 1 (sum of “POP” score /number of
questions answered).
Only 28 of 33 items assessing doctors’ treatment philosophies were compared
with UK and US data, as there was altered wording in 3 questions (Questions 18,
25 and 44) and 2 other questions were unique to the Australian questionnaire
(Questions 30 and 34), and comparison is therefore inappropriate.
Demographic and practice variables and response to individual questions were
compared between adult physicians and paediatricians using c2 for differences in
proportions. Overall mean “POP” scores were compared across demographic
and practice variables using ANOVA for differences in means. Backwards
stepwise regression of the variables found to be significant (p<0.05) on univariate
analysis was performed to identify independent predictors of “POP” score.
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Australian data was compared with UK and US data using c2 for differences in
proportions. Level of significance was defined as < 0.05.
5.3 Results
5.3.1 Respondents’ demographics
Three hundred doctors in total returned completed questionnaires (60%
response rate). Significantly more paediatricians (164/250 vs 134/250)
responded (p=0.004). Most respondents were males (72.8%) and practised in an
urban setting (87.2%). The median age was 47 years (47.0 for adult physicians
and 46.5 for paediatricians) with a range from 32 to 94 years. Respondents
worked in private practice (33.1%), were salaried hospital staff specialists
(44.8%) or academics (11.4%) (Table 5.1).
5.3.2 Respondents’ research experience
Many respondents had limited research experience with 31.5% having never
enrolled a patient in a RCT and 44.9% who had not enrolled a patient within the
previous year. Many (26.9%) were not currently involved in research at all, and
78.9% spent less than 30% of time in research activities. Only 56% had
published an article in the past 12 months (Table 5.1).
5.3.3 Comparison between paediatricians and adult physicians
Demographic data were similar between paediatricians and adult physicians.
There were more hospital staff specialists (51.5% vs 36.2%, p<0.01) and females
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(34.1% vs 17.9%, p<0.004) among the paediatricians. Although research time
and publications were similar among both groups, fewer paediatricians had
experience with enrolling patients in trials (62.2% vs 76.3%, p<0.009) (Tables 5.1
and 5.2).
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Table 5.1: Comparison of demographics and research experience of adult
physicians and paediatricians who responded to the questionnaire on
attitudes to RCTs (questions 1 to 11)
Demographics and research experience Adult Physicians Paediatricians Total p value*
N % N % %
Specialty (298) 134 45.0 164 55.0 298
Gender (298) Male 110 82.1 107 65.2 217 72.8 0.004
Primary setting (298) Private practice 42 31.3 44 26.8 86 28.9 0.3
Teaching hospital 64 47.8 96 58.5 160 53.7
Both teaching hospital
and private practice
10 7.5 9 5.5 19 6.4
Others** 18 13.4 15 9.1 33 11.1
Appointment (290) VMO/private practice
(fee for service)
45 35.4 51 31.3 96 33.1 0.01
Staff specialist
(salaried)
46 36.2 84 51.5 130 44.8
Academic (salaried) 22 17.3 11 6.7 33 11.4
Other 14 11.0 17 10.4 31 10.7
Location of practice (288) Urban 113 88.3 138 86.3 251 87.2 0.7
Rural 15 11.7 22 13.8 37 12.8
Patients seen per week
(293)
0 14 10.8 11 6.7 25 8.5 0.04
1 to 20 25 19.2 53 32.5 78 26.6
21 to 50 47 36.2 59 36.2 106 36.2
>50 44 33.8 40 24.5 84 28.8
Ever enrolled patients in an
RCT (295)
Never 31 23.7 62 37.8 93 31.5 0.009
Patients enrolled in an RCT
in the last year (285)
0 46 35.9 82 52.2 128 44.9 0.01
1 to 10 42 32.8 46 29.3 88 30.9
>10 40 31.3 29 18.5 69 24.2
Research time (294) no research 36 27.5 43 26.4 79 26.9 0.5
<30% 68 51.9 85 52.1 153 52.0
30-50% 12 9.2 22 13.5 34 11.6
>50% 15 11.5 13 8.0 28 9.5
Articles published in the
last year (293)
None 56 42.7 73 45.1 129 44.0 0.7
1 14 10.7 60 13.0 35 11.9
2 24 18.3 23 14.2 47 16.0
3 14 10.7 12 7.4 26 8.9
>3 23 17.6 33 20.4 56 19.1
*p value for differences in proportions between adult physicians and paediatricians
** 5 community, 4 government, 7 research, 12 retired and 5 others
( ) = number of responses to each question; RCT = randomised controlled trial
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Table 5.2: Comparison of adult physicians’ and paediatricians' treatment
philosophies and attitudes to trials (questions 12 to 44)
Question Response Adult
Physicians
Paediatricians p
value
N/T % N/T %
134 164
future generations of patients (society) 11/130 8.5 21/163 12.9 0.5Q12. As a doctor my primary commitment is to:
present patients (individual) 115 88.5 137 84.0
I enter the patient in a clinical trial if one
exists
50/123 40.7 49/154 31.8 0.3Q13. When there is controversy in the literature as to
which treatment is best:
I personally select a treatment for the
patient
71 57.7 102 66.2
caring for individual patients 118/130 90.8 144/160 90.0 0.8Q14. If I had to choose, I would say my primary task is:
contributing to scientific knowledge 12 9.2 16 10.0
clinical skills with patients 84/121 69.4 101/157 64.3 0.4Q15. In my hospital, doctors are given more reward for:
contributing to scientific knowledge 34 28.1 54 34.4
true 13/125 10.4 14/161 8.7 0.6Q16. If written informed consent was not required, I
would approach more patients to enter clinical trials makes no difference 112 89.6 147 91.3
seek major input from my patients 118/127 92.9 156/159 98.1 0.03Q17. When making critical and controversial decisions,
I usually: • do not seek major input from my patients 9 7.1 3 1.9
none 3/126 2.4 6/156 3.8 0.07
some 72 57.1 80 51.3
half 11 8.7 4 2.6
most 29 23.0 42 26.9
Q18. Ideally I would like to refer or enter the following
proportion of my potentially eligible patients into RCTs:
all 11 8.7 24 15.4
totally clinical work 16/126 12.7 15/158 9.5 0.2
mainly clinical work 77 61.1 97 61.4
equally and research 18 14.3 33 20.9
mainly research 10 7.9 12 7.6
Q19. The time I devote to publications, lectures and
research commitments, compared to clinical work, is
relatively:
totally research 5 4.0 1 0.6
dependent on my research activities 16/131 12.2 14/161 8.7 0.3Q20. My income is:
not dependent on my research activities 115 87.8 147 91.3
my research contribution 23/130 17.7 19/159 11.9 0.4
how I helped individual patients 97 74.6 125 78.6
Q21. I would like to assess how successful I was as a
physician by:
(both) 10 7.7 15 9.4
too involved with my patients 103/120 85.8 124/147 84.4 0.7Q22. I would rather be somewhat:
too detached from my patients 17 14.2 23 15.6
treat the patient off the study 124/124 100.0 155/157 98.7 0.2Q23. If a patient refuses to participate in an RCT, I
would: refer the patient to another doctor 0 0.0 2 1.3
my interpersonal skills with patients 100/128 78.1 124/161 77.0 0.3Q24. I would rather be known for:
my research accomplishments 26 20.3 29 18.0
increases when a patient is in a clinical trial 59/128 46.1 70/158 44.3 0.4
decreases when a patient is in a clinical trial 8 6.3 5 3.2
Q25. Overall I feel the quality of patient care:
does not change when a patient is in a
clinical trial
61 47.7 83 52.5
my clinical experience 57/129 44.2 71/158 44.9 0.8Q26. When published data and my clinical
judgement conflict, I am more likely to rely on: published data 69 53.5 85 53.8
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Question Response Adult
Physicians
Paediatricians p
value
N/T % N/T %
true 34/127 26.8 45/160 28.1 0.8Q27. RCTs restrict my ability to individualize patient
care makes no difference 93 73.2 115 71.9
low 105/120 87.5 143/159 89.9 0.5Q28. In my hospital the pressure to participate in an
RCT is relatively: high 15 12.5 16 10.1
Q29. Detailed monitoring of my management of trial
patients deters me from participating in RCTs:
yes 14/126 11.1 16/160 10.0 0.8
Q30. The increased paperwork involved in treating
patients on trials deters me from participating in RCTs:
yes 50/127 39.4 58/160 36.3 0.6
often feel disappointed 36/125 28.8 42/154 27.3 0.8Q31.When a potentially eligible patient chooses not to
enrol on a trial that I have suggested, I: seldom feel disappointed 89 71.2 112 72.7
Q32. Frequent publications are important to my career
advancement:
yes 61/131 46.6 76/162 46.9 1.0
I am often reluctant to participate 63/123 51.2 78/151 51.7 0.9Q33. When a protocol includes a treatment that is more
aggressive than I would usually give: it makes no difference 60 48.8 73 48.3
I am often reluctant to participate 54/122 44.3 55/151 36.4 0.2Q34. When a protocol includes a treatment that is less
aggressive than I would usually give: it makes no difference 68 55.7 96 63.6
Q35. I am reluctant to participate in a trial that may
randomise the patient to a ‘no treatment’ group:
yes 46/127 36.2 34/158 21.5 0.006
Q36. The opinions of the patient’s usual doctor
regarding RCTs affects my decision to approach an
eligible patient:
true 47/124 37.9 56/156 35.9 0.7
Q37. The thought of having to spell out  details of a trial
discourages me from approaching eligible patients:
true 28/127 22.0 28/160 17.5 0.3
Q38. A major reason for my participation in RCTs is
that it financially benefits my institution or department:
agree 20/126 15.9 9/157 5.7 0.005
enhances my reputation 62/128 48.4 64/155 41.3 0.2Q39. Overall, involvement in randomised clinical trials:
does not enhance my reputation 66 51.6 91 58.7
enter the patient in an RCT if I am aware
one exists
71/124 57.3 83/155 53.5 0.5Q40. When I am personally uncertain as to which
treatment is best, I am likely to:
personally select a treatment 53 42.7 72 46.5
Q41. If research activities were to enhance my income,
I would enter more patients in RCTs:
agree 36/127 28.3 36/160 22.5 0.3
clinical issues 99/130 76.2 117/160 73.1 0.8Q42. I am more likely to attend a conference that
focuses on: research issues 26 20.0 37 23.1
Q43. The patient’s right to select treatments is more
important than knowledge advancement:
true 91/128 71.1 109/158 69.0 0.7
increase my patient population 10/123 8.1 4/158 2.5 0.04
lose patients I might otherwise keep 10 8.1 7 4.4
Q44. When I participate in a randomised
clinical trial, it is more likely that I:
it makes no difference to my patient
population
103 83.7 147 93.0
N/T = number of responses/ total number of adult physicians or paediatricians who answered that question
RCT= randomised controlled trials
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Responses to the questions assessing treatment philosophies were also similar
between paediatricians and adult physicians. However, adult  physicians were
more reluctant to participate in RCTs involving placebo use (36.2% vs 21.5%,
p<0.006), more frequently thought trial participation affected their patient
population (16.2% vs 6.9%, p<0.04) and more often identified financial benefits
for their institution or department as a reason for trial participation (15.9% vs
5.7%, p<0.005).
5.3.4 Comparison of doctor demographics with “POP” score
Univariate analysis showed that doctors who were younger (p<0.0001), in
salaried positions (p<0.0001) or in urban settings (p<0.0001) had higher “POP”
scores (ie were more research-oriented) than doctors who were older, in private
practice or in rural settings respectively. There was an association between
number of patients seen per week and mean “POP” score, with clinicians who
saw fewer patients having a higher “POP” score (p<0.0001). Research
involvement (i.e. experience with enrolling patients in trials, time assigned to
research activities and number of publications in the last year) also correlated
with higher “POP” scores (all p<0.0001).  On multivariate analysis three
independent variables were found to significantly predict “POP” scores: the
presence of any allocated research time (8.6% higher “POP” score (95% CI
5.6%, 11.5%, p<0.0001)); history of enrolling a patient in a RCT in the past (4.2%
higher “POP” score (95% CI 1.5%, 7.0%, p=0.003)); and the doctor’s age
(decrease by 0.1% for each year increase (95% CI 0.06%, 0.3%, p=0.042)). The
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overall R2 for the model was 0.162 (ie 16.2% of participants’ mean “POP” score
can be explained using these 3 variables) (Table 5.3).
Table 5.3: Comparison of mean "POP" score by doctors' demographics and
research experience
Doctors' demographics N Mean "POP" score
(95%CI)
p value
Age median = 47 years 296 0.44 ( 0.43 , 0.46 ) 0.01
Gender Male 216 0.44 ( 0.42 , 0.46 ) 0.5
Female 80 0.45 ( 0.43 , 0.48 )
Adult physician vs paediatrician Adult physician 132 0.44 ( 0.42 , 0.46 ) 0.6
Paediatrician 164 0.45 ( 0.43 , 0.46 )
Oncologists vs nononcologists Oncologists 12 0.52 ( 0.41 , 0.63 ) 0.03
Non oncologists 285 0.44 ( 0.43 , 0.45 )
Appointment Staff specialist/academics 163 0.47 ( 0.45 , 0.49 ) 0.0001
VMO/private practice 97 0.40 ( 0.38 , 0.42 )
Primary setting Salaried 180 0.47 ( 0.45 , 0.49 ) 0.0001
Fee for service 86 0.38 ( 0.36 , 0.41 )
Location of practice Urban 252 0.45 ( 0.44 , 0.47 ) 0.0001
Rural 37 0.38 ( 0.35 , 0.40 )
Patients seen per week 1 to 20 78 0.49 ( 0.46 , 0.52 ) 0.0010
21 to 50 106 0.44 ( 0.42 , 0.46 )
51 to 100 79 0.41 ( 0.39 , 0.43 )
>100 6 0.37 ( 0.23 , 0.51 )
Ever enrolled patients in RCT Never 93 0.40 ( 0.37 , 0.43 ) 0.0001
Have enrolled pts 203 0.46 ( 0.45 , 0.48 )
0 128 0.41 ( 0.39 , 0.43 ) 0.0001
1 to 10 88 0.44 ( 0.42 , 0.46 )
Patients enrolled in RCT in the last
year
>10 70 0.50 ( 0.47 , 0.53 )
Research time None 79 0.37 ( 0.36 , 0.39 ) 0.0001
<30% research 154 0.44 ( 0.42 , 0.46 )
30 to 50% research 34 0.53 ( 0.49 , 0.56 )
50 to 70% research 11 0.56 ( 0.50 , 0.62 )
>70% research 17 0.61 ( 0.56 , 0.66 )
Articles published in the last year 0 129 0.40 ( 0.38 , 0.41 ) 0.0001
1 35 0.45 ( 0.41 , 0.49 )
2 47 0.45 ( 0.41 , 0.48 )
3 27 0.47 ( 0.42 , 0.52 )
>3 56 0.55 ( 0.51 , 0.58 )
Mean "POP" score ranges from 0-1: 1= extreme researcher, 0= extreme clinician
N= number of responses to each question
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5.3.5 Comparison with UK and US data
Comparison of Australian data with UK/US needs to be made with caution as the
Australian study was conducted 5-15 years later, and attitudes are likely to have
changed. The Australian responses to 9 of 28 questions significantly differed
from UK and US responses (Questions 13, 16, 28, 31, 36, 38, 39 and 40, and US
data only for 27–Table 5.4). There appears to be less motivation for Australian
general physicians and paediatricians to participate in RCTs compared with
cancer specialists from the UK and US (doctors reporting relatively low pressure
from hospitals for participation, little financial incentive for participating institutions
and trial involvement not being perceived to enhance their reputation) and were
less concerned about participation (reporting that written consent requirements
and the opinions of the referring doctors have less influence on their approaching
patients for trial participation, seldom feeling disappointed when eligible patients
chose not to participate, and less often feeling their individual patient care is
restricted by RCTs). Australian doctors were also more likely to personally
choose treatments for their patients rather than enter them in a trial if there is
controversy in the literature (p<0.0001) or when they were personally uncertain of
best treatment (p<0.0001).
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Table 5.4: “POP” questions which elicit significant response differences
between Australian and UK/ US doctors
Questions Choices Aus
(300)
UK
(357)
US
(1485)
Aus vs
UK
Aus vs
US
% % % p Value p Value
I enter the patient in a clinical trial if one exists 36 84 85 0.0001 0.0001Q13: When there is controversy in the literature as to
which treatment is best: I personally select a treatment for the patient 64 16 15
caring for individual patients 90 95 86 0.02 0.05Q14: If I had to choose, I would say my primary task is:
contributing to scientific knowledge 10 5 14
true 10 36 15 0.0001 0.02Q16:  If written informed consent was not required, I would
approach more patients to enter clinical trials makes no difference 91 64 85
seek major input from my patients 96 93 92 0.1 0.03Q17: When making critical and controversial decisions, I
usually: • do not seek major input from my patients 4 7 8
low 73 75 63 0.5 0.002Q19: The time I devote to publications, lectures and
research commitments, compared to clinical work, is
relatively:
high 28 25 37
dependent on my research activities 10 5 10 0.01 0.8Q20: My income is:
not dependent on my research activities 90 95 90
my interpersonal skills with patients 80 73 0.01Q24: I would rather be known for:
my research accomplishments 20 27
my clinical experience 45 50 55 0.2 0.003Q26: When published data and my clinical judgement
conflict, I am more likely to rely on: published data 55 50 45
true 28 77 0.0001Q27: Randomised clinical trials restrict my ability to
individualize patient care makes no difference 72 23
Q28: In my hospital the pressure to participate in a
randomised clinical trial is relatively:
low 89 66 64 0.0001 0.0001
high 11 34 36
yes 11 21 9 0.0004 0.4Q29: The need for detailed monitoring deters me from
participating in randomised clinical trials: no 89 79 91
often feel disappointed 28 53 58 0.0001 0.0001Q31: When a potentially eligible patient chooses not to
enroll on a trial that I have suggested, I: seldom feel disappointed 73 47 42
I am often reluctant to participate 51 51 40 1.0 0.0008Q33: When a protocol includes a treatment that is more
aggressive than I would usually give: it makes no difference 49 49 60
true 36 74 70 0.0001 0.0001Q36:The opinions of the patient’s usual doctor regarding
randomised clinical trials affects my approaching eligible
patients
false 64 26 30
true 20 41 23 0.0001 0.2Q37: Having to spell out all the details of a trial
discourages me from approaching patients to participate: false 80 59 77
agree 10 40 54 0.0001 0.0001Q38: A major reason for my participation in trials is that it
financially benefits my institution or department: disagree 90 60 46
enhances my reputation 44 91 97 0.0001 0.0001Q39: Overall, involvement in randomised clinical trials:
does not enhance my reputation 56 9 3
enter the patient in a randomised clinical trial if I am
aware one exists
55 85 84 0.0001 0.0001Q40: When I am personally uncertain as to which
treatment is best, I am likely to:
personally select a treatment 45 15 16
true 69 74 75 0.2 0.04Q43:The patient’s right to select treatment options is
always more important than the advancement of science False 31 26 25
(For the purposes of comparing with US and UK data, answers which were outside the given choices were excluded)
( ) = number of respondents in the study
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5.4 Discussion
For most Australian physicians, primary allegiance is to the individual patient.
Active participation in research plays a limited role in professional activities, with
many having never participated in a RCT and only a minority assigning time for
research or publishing articles within the last year. When making decisions under
uncertainty, many preferred to personally select a treatment rather than enter a
patient in a clinical trial. There are few perceived rewards for trial participation
and peer group influence plays a minor role.
Australian paediatricians and adult physicians were similar in their attitudes to
RCTs. This finding is interesting because recruitment to non-oncology RCTs is
usually thought to be more difficult for children (75;76). This suggests that the
added complexities of the parent-child interaction, rather than doctor factors, are
the causes of this difference. Demographic and practice data were similar for
both groups with a higher proportion of females and hospital staff specialists
among the paediatricians, reflecting the practice trend in Australia (159). Limited
experience with RCTs among paediatricians may reflect the small number of
paediatric trials available (19;45).
Allocated research time, experience with enrolling patients in trials in the past
and age have the strongest correlation with mean “POP” scores, with younger,
salaried doctors with research experience and time assigned for research
working in an urban setting having the most favourable attitude towards trial
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participation. This is consistent with findings from the previous study (Chapter 4)
that doctors with research experience perceived most benefits for trial
participation and those in private practice the least (158).
Overall, Australian data were similar to that from the UK and US, with differences
reflecting a smaller impact of RCTs in Australia. However, these differences may
partly be due to changes over time (this study was conducted some 5 –15 years
later). Another possibility is that there are different attitudes to RCTs among
different specialties, as the UK and US studies were with cancer specialists (48),
and respondents in our questionnaire were physicians from a broad range of
subspecialties. Although Australian haematologists/oncologists responses were
closer to US/UK oncologists compared with other Australian physicians,
comparison with the subgroup of Australian haematologists/oncologists is difficult
to interpret due to the small number (twelve) of Australian
haematologists/oncologists who participated. There is reported reluctance for trial
participation among cancer specialists in the literature. Our sample of
predominantly non-oncologists were even less “researcher-oriented” in their
treatment philosophies.
5.5 Conclusions
Australian doctors are clinician-oriented rather than research-oriented in their
attitudes to RCTs participation, highlighted by their personal preference for
selecting treatment to referring for trial participation in the face of treatment
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uncertainty. Research plays a small role in their professional activities, and the
importance of research participation is undervalued. However, the association
between doctors’ attitudes to RCTs and modifiable factors such as allocated
research time and experience with enrolling patients in trials suggests that there
is potential for attitude change.
The crisis in clinical research has been highlighted by the Clinical Research
Roundtable in the US (160) and also by the National Health and Medical
Research Council (NHMRC) in Australia (161). Taskforces have been formed to
address this issue. This study identified major structural reasons for research
having a low priority for clinicians and suggests that the problems in clinical
research are unlikely to be resolved unless the role of research is restructured in
a setting that is primarily clinically orientated.
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Chapter 6 - Parents’ attitudes to children’s participation in
randomised controlled trials (focus group research)
6.1 Introduction
Recruitment issues are thought to differ for adults and children (75), with
children’s recruitment being more difficult (148). With the recognition of the need
for the inclusion of children in trials, paediatric RCTs are increasingly demanded
by legislative bodies (24;162).
Because of children’s vulnerability and inability to give full informed consent,
parents play a key role in making decisions for trial participation on their behalf
There are very few studies of parental attitudes to children’s participation in trials
(see section 2.4.1).
This study explored parents’ attitudes to children’s participation in trials,
identifying factors that influence the decision for participation, and perceived risks
and benefits for parents. It also compared responses across a range of parents
of children with health problems of varying severity (from none to life
threatening). Although this study is limited to reporting parental claims rather than
observation of parental response, it offers suggestions for methods of increasing
trial participation from a parent’s perspective, which could be tested in future
studies. The recognition of motivators and barriers to trial participation for parents
may aid in the design of future trials and recruitment strategies to enhance
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participation for children in trials that meet appropriate scientific and ethical
standards.
6.2 Participants and methods
6.2.1 Participants
The ethics committee of the Children’s Hospital at Westmead (CHW) approved
the focus group research and written consent was obtained from participants.
Purposive sampling of parents was employed to ensure that all groups with
unique views were represented (163). Relevant paediatricians and researchers
from the hospital were requested to identify parents who may provide a range of
views to participate in the focus groups. Parents were recruited from The
Children’s Hospital at Westmead (a tertiary referral teaching hospital for sick
children)  and a local primary school. Parents recruited from CHW were from the
Oncology Unit (“oncology parents” with children who have life threatening
illness), the Renal Treatment Centre (“renal parents” with children who have
chronic conditions), various research groups involved in RCTs (“trial parents”)
and hospital wards (“hospital parents” with hospitalised children). Interested
parents were then invited by the researcher to participate in the focus group
discussions. Due to poor focus group attendance of parents of hospitalised
children, other suitable parents were approached to participate in individual
interviews in the ward. Parents from a local primary school (“school parents” with
healthy children) were invited to participate in the focus groups by advertisement
in the school newsletter with endorsement by the school principal. Because of
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poor response, additional parents were personally invited, with an improvement
in response.
The poor response from parents for focus group participation is interesting.
Parents of healthy children were generally indifferent about participating in
children’s health research, as demonstrated by the poor response to the school
newsletter, but responded well to personal invitation. As expected, parents who
had previously participated in research were most willing to be involved in the
focus groups. Parents of children who were admitted to hospital responded
particularly poorly to focus group participation, despite verbally agreeing to come.
However, many parents were willing to be interviewed in the ward. This may be
because it was more convenient for parents to be individually interviewed near
their sick child at a time suitable to them than to attend a focus group meeting
located in another part of the building held at a set time. The poor focus group
attendance may also reflect parents’ preoccupation with their child’s acute illness
during hospitalisation.   This observation has implications for the optimal timing of
when and how to approach parents for focus group participation.
6.2.2 Focus groups
Semi-structured group discussions were conducted using an open-ended
questioning approach using a “prompts sheet” (Appendix F). To ensure free
discussion and interaction, parents from different recruitment sources attended
separate groups.  All participants completed a socio-demograpic questionnaire
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(Appendix G). A medical researcher unknown to the participants facilitated the
discussions, with an observer taking field notes. Each session lasted 60 minutes
and was audiotaped. Recruitment ceased when informational redundancy was
reached (when no further information was gained), after 4 focus groups and 5
individual interviews involving 33 participants.
6.2.3 Analysis
The audiotapes were transcribed and checked against field notes for accuracy
and inclusion of non-verbal details. The data were organised and coded into
discrete categories using the constant comparative method where each item is
compared with the rest of the data to establish analytical categories that are
mutually exclusive (153;154) and then further examined to identify emergent
over-arching themes (152). Analyses of differences in responses between
participants from the various recruitment sources, levels of education, age,
gender, ethnicity and research experience subgroups were explored.
6.3 Results
Thirty-three parents participated in the study. The parents varied in age, gender,
ethnicity, level of education, geographic locality and research experience (Table
6.1).
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Table 6.1: Characteristics of participating parents
Characteristics of participating parents No. (%)
Source
     School (healthy children) 9 (27)
     Inpatients (children with acute illness) 6 (18)
     Renal Treatment Centre (children with chronic illness) 5 (15)
     Oncology Unit (children with life threatening illness) 6 (18)
     RCT participants (children with research experience) 7 (21)
Relationship to child
     Father 4 (12)
     Mother 29 (88)
Age
     21 – 30 years 5 (15)
     31 – 40 years 18 (55)
     41 – 50 years 9 (27)
     51 – 60 years 1 (3)
Level of education
     Up to School Certificate (junior high) 14 (42)
     Higher School Certificate (senior high) 7 (21)
     Tertiary education 12 (36)
Ethnic origin
     Australian/New Zealand 26 (79)
     Asian 4 (12)
     Eastern European 1 (3)
     Pacific Islands 1 (3)
No of children
     1 9 (27)
     2 13 (39)
     3 8 (24)
     4+ 3 (9)
Residence (distance from CBD)
     0-20km 2
     21-50km 23
     51-100km 4
     >100km 4
Previous participation in RCTs
     Yes 9 (27)
     No 24 (73)
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To achieve the numbers required, “hospital parents” were approached to
participate in either focus groups or individual interviews in the ward and some
“school” parents were personally invited to participate. The proportion of parents
who attended the focus groups (number attended/ number agreed to attend) was
clearly significantly different among the five groups of parents (Fishers exact test
2p < 0.0001), with the lowest response from parents of hospitalised children
(Table 6.2).
Table 6.2: Parents’ focus group participation
Source of recruitment Approached1 Verbal
agreement of
attendance2
Attendance3 %
Attendance4
RCT participants 15 9 7 78
Oncology Unit 15 12 6 50
Renal Treatment Centre 19 10 5 50
Hospital Inpatients
       (focus group) 46 17 0 0
       (individual interview) 10 6 6 100
Total 6 26
School
       (newsletter) 760 1 1 100
       (personal invitation) 17 8 8 100
Total 9 100
1 Number of parents approached by investigator
2 Number of parents who verbally agreed to attend the focus group
3 Number of parents who attended the focus group
4 Number attended/ number agreed to attend
Participant views were organised into factors influencing parents’ decisions for
trial participation for their child (Figure 6.1). As participant responses were
different for parents from different sources of recruitment (a surrogate for their
child’s health status), these differences are highlighted in the results below,
which are based on views reported by parents rather than observation of their
actual response.
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Figure 6.1: Factors influencing parents’ decisions for trial participation
Factors favouring
non participation
Factors favouring
participation
Gains-hazard considerations
Risks Benefits
Side effects of new medication Free medication
Randomised to the less effective treatment New medication
Additional blood tests An alternative treatment option
Extra hospital visits Source of hope
Too time consuming Doing their best for their child
Extra travel Helping others
Other financial disincentives Better care of their child
Better monitoring
Additional information about child’s condition
Increased access to healthcare professionals
Meeting others in similar situation
Parental factors
Beliefs and knowledge
General fear of research and researchers Research is important for children
Specific fear of child treated as “guinea pig” Gratitude for their child’s care
Lack of knowledge about trials Trials are beneficial for their child
Emotional response to trials
Protective parental instinct
Difficulty with consent by proxy
Child factors
Child’s condition
Healthy child Child has life threatening illness
Increased protectiveness Increased awareness of need for trials
Quality of life trials if child sick but stable
Child’s choice
Child’s choice (if non life threatening) Child’s choice
Trial factors
Placebo controlled trials Trials with active arms
Uncertainty and loss of control
Doctor factors
Own doctor not supportive of trial Own doctor supportive of trial
Informed by unknown researcher Informed by own doctor
Poor communication of trial information Good communication of trial information
*Italics denote modifiable factors
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6.3.1 Gains-hazard balance
Parents face a dilemma when making decisions about trial participation, weighing
the risks against the benefits of participation.
“..two ends of the scale, the fear of the unknown and the possibility that it
might resolve your child’s problem”.
6.3.1.1 Perceived benefits
Perceived benefits of trial participation include provision of free medication, which
may be otherwise very expensive and the chance to access new and effective
treatments not routinely available.
“They might get the new drugs that work..”
“..If there’s a chance of a slight improvement of quality of life …you are
able to take that risk.”
Some parents viewed trials as an alternative treatment option and a source of
hope. Some view participation as the best treatment option. Many liked
participating because it also contributes to helping other children.
“It’s reassuring to know something can be done (ie participation in a trial
when there are no other treatment options)..”
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“..it would show that I was doing the most that I could possibly do for the
child ….As a parent it is something I could do to help the child.”
“..there’s a part that we felt good about it, because we felt we had done
the best we could..”
“..the main benefit is the feel good factor…you feel like you’re not only
trying to help your child, but you’re trying to help other people’s children.”
 “You feel like you’re doing something for society, you’re
helping…contributing towards something.”
“Oncology” and “trial” parents also believed there were benefits for all
participants including better care and monitoring of their child, additional
information about their child’s health and underlying condition, access to
healthcare professionals, and the social benefits of meeting other parents and
children in similar circumstances. Overall, “trial” parents perceived most personal
gains from trial participation.
“Improved health care, improved knowledge and I think you’re better off..”
“..They’re the ones missing out (those not participating): we’re getting the
benefit.”
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6.3.1.2 Perceived risks
Safety issues were parents’ main concern regarding trials. Many preferred initial
testing of new treatments on adults. Parents, fearful of unknown side effects in
new experimental treatments, were more willing to participate in trials where
treatments had been previously tested.
“..I’d be worried about possible side effects … but otherwise, I wouldn’t
hesitate.”
“..if it’s … never, ever been used before.  That would be pretty scary, the
side effects..”
“..I would be more likely to say yeah… because they’re not using untried
treatments.”
The risk of their child being randomised to the less effective treatment also
worried many parents, who felt responsible if their child deteriorated.
“..it’s a worry thinking you’re doing the wrong thing…people don’t want to
…(be) the one being responsible once again.”
“..you don’t want to put them into a treatment that may, at the end of the
day, make them worse off than when they went in.”
“..If  it didn’t work, that was it”
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Parents identified many inconveniences for trial participation including additional
blood tests, hospital visits, time demands, travel, parking and other financial
disincentives. Long waiting times, inadequately equipped waiting rooms and their
child’s distress also added to the problem. Some thought the constant reminder
of their child’s illness may be stressful for parents.
“My son had the same thing, he had to go for injections and blood tests as
well, and I’m hopeless with needles, and I thought immunisations well
O.K. until they did the blood tests and he just screamed blue murder.  The
needle went with the patches, he was just completely beside himself.  It
wasn’t the pain, it was the fact that we had to hold him down.”
“For me to come down for my visit, by the time we stop and have lunch
and buy petrol, I’m looking at $50-60 each fortnight.”
“Keeping them still in the waiting room is a big job. And you have
appointments that are not on time, like 10 o’clock appointment and you get
home at 3 o’clock, stuff like that..”
“..The stress and anxiety … that goes on by continually being…assessed
and questioned and having to come back to hospital.”
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6.3.2 Parental factors
6.3.2.1 Parents’ beliefs and knowledge
All parents thought research with children is necessary for improving their health
and well being and believed children and adults’ responses to treatment often
differ.
‘Without research, there will never be a cure, or there will never be any
answers to all the questions that we have.  So, you have to do research
on children, it relates to children, so it’s very important..”
However, with the exception of “oncology” and “trial” parents who had a good
understanding about RCTs and the informed consent process, most of the other
parents had little knowledge about RCTs. Some were unaware that trials are
conducted with children. Many were confused between RCTs participation and
trying untested treatments. Some thought RCTs always involved placebo use.
Some parents thought children could not discontinue once they enrolled in a trial.
Many, believing that doctors and scientists already know which treatments are
superior, were not aware that RCTs are conducted only when there is equipoise
or uncertainty about best treatment.
“..initially my thought was it might be good drug against bad drug.  You
would be very worried that your child is going to get the bad drug…
whereas you’re saying that it is when you don’t know which drug is the
best.”
143
“..to randomly, what’s the word, ‘Pot-luck’ sort of thing, you playing with
the odds that …is one better than the other, you don’t know.”
Many parents were fearful of their child being a “guinea pig”, and being subject to
experimentation and exploitation. Some worried that researchers were more
concerned about the research results than their child’s welfare because “.. it’s not
their child..”
“They (the researchers) are worried about money.”
“I would be thinking ‘I don’t want my kid being a guinea pig here’… Are
they going to possibly use your child in an experimental way?”
However, “oncology parents” expressed gratitude for their child’s care and felt an
obligation to participate in trials.
“..we’re willing to give back what was given to us..”
“..I explained that it is for research and I said that in the past, lots of other
children have done things for research and that’s why your treatment is
better today.  I explained to her that it’s not going to help her but it could
benefit others in the future.”
“Trial parents”, despite negative responses from friends and family, believed trial
participation was personally beneficial for their child.
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“You feel for them (the children having blood tests), but you think you’re
doing good for them.”
“Our family and friends looked at us sideways, you know.  Like – you’re
going to let them do that?…Well, we looked into it … but we found
ourselves justifying ourselves to our parents and friends.”
6.3.2.2 Parents’ emotional response to trials
Despite overall support for paediatric research, many parents were reluctant to
involve their own child in research, preferring that they “..do it on someone
else..”. Many acknowledged their decisions are influenced by their protective
parental instincts, which may defy reason.
“It’s hard because, they (children) are such a precious thing to every
parent, but if we don’t research on somebody then others miss out on
some results that might come from it… someone’s got to be able to do it”
“..what happens to other people’s children, that’s fine, but when you’re
actually dealing with your own, the logic does get very much swayed by
the emotional attachment.”
“because of natural parental protectiveness, would want to protect their
children from anything that the child might not necessarily need.”
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Many parents found the responsibility of consent by proxy difficult, claiming they
would personally be willing to participate in a RCT, but were more hesitant about
their child’s participation.
“..It’s a lot easier to make a decision for yourself rather than for somebody
else.  Taking responsibility for other people is very difficult, because you
just don’t know if you’ve done the right thing.”
“I wouldn’t be as hesitant (about trial participation)  because you’re making
your own decision about your body.”
“..I would feel differently, but I may not act differently.”
6.3.3 Child factors
6.3.3.1 Child’s condition
Parents thought that those who had a child with a life threatening condition would
be more prepared to participate trials, in the hope of finding the “miracle cure”.
“Oncology parents” confirmed feeling they had no choice about trial participation
for their child’s cancer treatment. However, they and the “renal parents” were
reluctant to participate in trials addressing quality of life if their child’s condition
was stable, for fear of causing deterioration.
“..it’s like a big decision, depends on how desperate you are and what the
situation is.”
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“I think if the child was desperately ill, you would be prepared to try it.  I
would be worried about having the placebo.”
“..I would do anything to get the miracle cure.”
“..I didn’t feel like I had a choice at all.” (oncology parent)
“..I can’t do that (ie enrol in a quality of life trial), because at this stage I’ve
seen that everything is going along nicely and he’s happy and well, and I
just couldn’t warrant doing something like that, even though I know how
important it is …  He’s doing fine, I would rather not touch him..”
Many parents admitted their child’s illness influenced their support of research,
but reasoned that other parents, traumatised by the ordeal, may be unwilling to
participate in trials. They thought parents of healthy children do not have that
insight, and often trivialise minor illnesses and regard trial participation as an
unnecessary inconvenience.
“..you can be blasé, ‘ah that’s a common thing, you don’t need to know
about that…’  So, you don’t get involved..”
“..(if  he was well) am I going to drag him all the way here ?… But if he
was sick, and there was a chance that a new treatment might help him, I
would take the chance..”
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“..I am not prepared to take the risk if I have a normal child unless my child
has a certain disease, I think it’s alright.”
6.3.3.2 Children’s choices
Parents thought children’s preferences about trial participation need to be
considered, and judged teenagers capable of making this decision, particularly
for quality of life trials. However, parents preferred to make the final decision in
treatment trials for life threatening situations.
“..I don’t think anybody should be put through it without their total
understanding and total assent to it..”
“..If a child knows that he’s sick and he knows something could go wrong,
I think it boils down to the child - he must make that decision because it’s
his life, it’s his future, it’s not the parents, it’s his body.”
“..well research, yes.  Treatment, unfortunately, is not optional (re children
making choices)”
 “..if they were going to die without it, then I would make the decision for
them, but .. if it were only going to prolong their life …I would give them
the right to choose that because they are choosing the quality of their
life..”
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6.3.4 Trial factors
6.3.4.1 Placebo controlled trials versus active trials
Most parents preferred newer or more aggressive treatments to standard
treatments or placebo, believing they were more likely to be effective.
“He would be peeved off if he got the jelly beans … he would want the real
thing..”
 “..if it were life threatening for your child, or the chances are it could
become life threatening, you certainly wouldn’t want to think that maybe
your child had the placebo.”
“..am I going to drag him all the way here to get all those needles and to
find out that he had nothing ?…so I would seriously think about
participating in a placebo trial..”
“..I would probably go for that (trials with active treatment arms), because
you get treatments, so long as the sugar pill business isn’t involved..”
Few parents understood the rationale for placebo use, equating placebo with
abandonment of treatment. Many parents preferred trials with all active arms to
placebo controlled trials because they reasoned their child would still be
receiving effective therapy. Parents were particularly opposed to placebo-
controlled trials for treatment of life threatening conditions.
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“..that’s just like going to the doctor and them saying well we are just not
going to treat this child.”
6.3.4.2 Trial uncertainty
Many parents, misunderstanding the concept of randomisation, assumed
treatment decisions were made by doctors or researchers. Some thought
“randomisation” meant that children were randomly chosen to participate in trials.
Many parents were hesitant about random allocation of treatment, preferring their
doctor to choose “the best treatment.”  Some parents preferred trying untested
treatment by trial and error to the uncertainty of randomisation.
“.. we are all scared of the unknown, what’s going to happen..”
“..I like to know where things are going.  I think you can still trial them (i.e.
the new treatment)… on an individual control basis …trial and error.”
Parents of chronically ill children were concerned about blinding to treatment
because it accentuates their sense of loss of control. Many “oncology parents”
wanted to be able to double-check their child’s medication because of previous
experiences with drug errors. Many claimed they would be more willing to
participate in trials that are not blinded.
“..I’d have a problem with the checking mechanism.”
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“..mistakes are still being made from nurses, nurses can’t even go back
and double check things because they can’t have it written in the same
manner in the medication chart.”
“..I think you will find that most oncology parents become control freaks.”
“..there is really a lack of control when you walk into this hospital …
Everyone is deciding for you, telling you what to do …but you do need to
(have) as much control as … you want to take… you need to know that
this child is taking this …If you take that away, it’s like, I can’t control his
health, he’s sick, I can’t help him..”
6.3.5 Doctor factors
Parents claimed they would seek their doctor’s advice on trial participation
because they trusted their opinion and medical knowledge. They appreciated
being informed about trials relevant for their child, and thought this should be the
doctor’s duty. Many were indignant that doctors were sometimes selective about
informing parents about relevant trials.
“..I would consult my doctor, and get the best advice I can.”
“.. I would go via the doctor, they have had enough experience to know …
the doctors need to be involved and make that decision.”
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“..it was wonderful that the paediatrician told me (about the
trial)…otherwise I would know nothing about it.”
“..it’s not for doctors to decide I don’t think who deserves to have what.
It’s for parents to decide if they want to do something better for their
children.”
 “I don’t think you can ever underestimate the value of giving people
information… they understand that they have got a choice, I don’t think the
doctors should make that choice … it’s assuming something that they
don’t know.”
6.3.6 Parents’ suggestions
6.3.6.1 Improved communication
Because of perceived poor public knowledge about trial methods and RCTs
currently being conducted, parents suggested advertising with posters and
pamphlets in health clinics, positive media presentations and informing via
hospital internet websites. They also acknowledged the importance of “word of
mouth”, and suggested research newsletters or telephone “hotlines” for
interested parents.
“Letting the general public know that there are a lot of different trials going
on at different trials.  It may not be applicable to them at that time, to be
aware that there is a lot of study going on …It’s just there in the back of
your mind, a little bit of knowledge.”
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“I think this word of mouth thing is quite important, because we all know
people with children.”
Parents’ attitudes to trials were thought to be influenced by how the trial was
presented to them and how they were treated. Some parents preferred being
informed about trials by their own doctor whom they trust, rather than an
unknown researcher. Parents’ understanding about trials may also improve by
simplifying information.
“..the most important thing I found was being treated like an intelligent
person … if it is explained to people … you are more likely to get a
positive sort of response.”
“..I think also it’s how it’s explained to you as well, because if someone
came up to me, and I didn’t know anything at all about trials, I’d be
thinking trials to me sound experimental, placebo to me sounds like it’s not
a real drug.  So, I think it’s all depends on how it’s been worded and how
it’s been explained..”
“..A lot of it’s bedside manner and the need for the doctor to communicate
and to get on the right side of you rather than to set you off against him
from the start.”
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“..the obstetrician should have informed me not someone I had no
connection with..”
 “..Simplifying the information.  Making it like user friendly, so the average
Joe off the street can simply read something like this..”
6.3.6.2 Increasing incentives and decreasing disincentives
The provision of a child-friendly play area, minimising waiting times and
reimbursement for travel and parking costs were practical suggestions for
reducing disincentives.
“I just think in the area of the behaviour thing, that there could be an area
where the children can be put in, not like caged in or anything like that, like
an area that’s fenced in, with lots of toys.”
Some “trial parents” found the offer of the proven effective treatment at the
completion of the trial a powerful incentive, particularly for placebo controlled
trials where they were desperate to access the new treatment.
“..I was at the end of my rope…if it was the placebo, well that means that
we can try the real thing anyway.”
6.3.6.3 Aids for decision making
As decisions for trial participation are often difficult for parents, aids for decision
making such as a parent discussion group was suggested.
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“I would be very happy to be a part of that (a parent discussion group) and
to make an informed decision, so I’ve got it all in front of me, whether I
understand it or not, but to be there, to be helped by someone, perhaps to
be encouraged by someone to make an informed decision.”
 “..It’s good to hear other people’s opinions, it would help you to make your
own mind up.”
6.4 Discussion
6.4.1 Risk benefit considerations
(See Figure 6.1 for factors influencing parents’ decisions for trial participation). In
this study, risk-benefit considerations were important for parents in deciding
about trial participation. Parents perceived risks such as side effects of the new
treatment, being randomised to the less effective treatment and inconveniences
that are often modifiable (such as additional blood tests, extra hospital visits,
travel and costs and being too time consuming). These are balanced against
perceived benefits such as free medication, the opportunity to access new
treatments, better care of their child, greater access to healthcare professionals
and health information, the support of meeting others in similar circumstances,
the offer of hope and altruistic benefits. Although many factors are fixed, some
factors are modifiable (see factors in italics on Figure 6.1). Modifying these may
enhance trial participation. Parents also need to be informed that formal clinical
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trials are better than informal trial and error in reducing risks, increasing benefits,
and more accurately distinguishing therapeutic advances.
Parents from this study who were willing to participate in trials viewed the
benefits of trial participation outweighed the risks, confirming Zupancic’s findings
of the importance of risk benefit assessments for parents (88). The child’s health
status, however, modifies the risk benefit balance. In this study, parents of
chronically and terminally ill children were prepared to take greater risks in
treatment trials but not necessarily in quality of life trials because they highly
valued curing their child’s illness. In Morrow’s paper, factors influencing accrual
to cancer “treatment” trials are thought to be different from “control” trials (47).
6.4.2 Differences between groups
The response from the “oncology” and “trial” parents differed from the other
parents. They were more knowledgeable about trials, viewed participation as
beneficial for their child and were more willing to consider participation,
suggesting that increased knowledge about trials may enhance trial participation.
However, there is conflicting evidence that increasing patients’ knowledge about
trials improves trial participation (59;164). Although “trial” parents in our study
had the most positive views about trial participation, it is unclear whether they
participated in trials because they had positive views beforehand, or whether
their views changed as a result of the positive experiences with trial participation.
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6.4.3 Parents’ emotional response to trial participation
The finding that parents’ emotional responses often hindered rational decision
making for trial participation is not surprising. Parents’ fear of experimentation
and mistrust of researchers may reflect society’s reaction to unethical
experimentation on human subjects, which led to the development of the
Nuremberg Code and Helsinki Declaration to protect the interest of research
participants (165). Parents were also uncomfortable with “blinding” and random
allocation of treatment, as has been previously noted (91;166;167). Medical
research may require more effective education to overcome existing negative
attitudes and unfounded fears. Parents need to be informed that a double
standard exists where treatments given outside clinical trials may cause harm
from unpredicted adverse events and are less stringently reviewed than protocol
treatments within the trial context. They also need to know that treatment offered
to the control group should be the current best standard treatment, while
treatment allocated to the experimental group is hypothesised to be as good as
or better than standard treatments. Parents need help to understand that the
rationale for blinding is to ensure that the assessment of the child’s response to
treatment is accurate and not biased by physician expectations. In future
research, it would be critical to explore the role of parental fears in the decision
making process and develop strategies for addressing parental fears.
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6.4.4 Parents’ treatment preferences
Parents’ negative attitudes about placebo use, although partly caused by lack of
understanding, may reflect their optimism for new treatments. This view,
however, may not be totally unfounded. Although there have been notable
exceptions (168), in many trials conducted in the past few decades new
experimental treatments have had better outcomes than standard treatments
(116). Parents’ preference for newer and more aggressive treatments, however,
contradicts their stated concerns about the safety of newer treatments.
6.4.5 The doctor’s role
The importance of the doctor’s role was again highlighted in this study where
parents acknowledged seeking their doctor’s advice regarding participation. This
is similar to adult studies where patients rarely participate in a trial unless actively
recommended to do so by their physician (50).
Parents in this study thought that doctors should inform all eligible patients about
relevant trials. However, in the previous study from Chapter 4 (158) and other
studies (83), doctors acknowledged preferentially informing patients whom they
considered likely participants, about trials and were more likely to invite those
who were less severely ill to participate in trials because of concerns about
informed consent (83). Surprisingly, parents in this study thought that their
willingness to participate in trials correlated with their child's severity of illness.
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Understanding parent’s attitudes may encourage researchers in approaching
parents, particularly those who are considered less likely candidates.
6.5 Conclusions
By understanding parents’ attitudes to trial participation, recruitment to paediatric
trials may be improved. Researchers should regard parental risk-benefit
considerations when planning trials, and alter modifiable factors whenever
possible to enhance participation (such as by minimising additional blood tests
and hospital visits and by reimbursing travel and other costs). There needs to be
better education of the public about trials, and improved communication between
researchers and parents (such as by simplifying trial information for parents). The
development of decision aids incorporating all the factors that influence parental
decisions for trial participation, including addressing the impact of parents’
emotional response to their child’s involvement in trials, may help parents with
the decision making process.
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Chapter 7 - Conclusion
7.1 Overview
Problems with recruiting adequate numbers of children for randomised controlled
trial participation are commonly faced by researchers working with children. This
thesis is one of the first major attempts to address the issues surrounding the
recruitment of children to RCTs.
The method by which potential participants are approached for trial participation,
the influence of their health care provider and the attitude of potential participants
(or their parents, in the case of children) are critical to the understanding of the
decision making process for trial participation. These three important areas are
explored in this thesis using both qualitative and quantitative techniques.
7.2 Key findings
7.2.1 Recruitment strategies used to encourage participation in randomised
controlled trials (systematic review)
Referral by health care professionals had the highest consent rates when
potential candidates were initially approached for trial participation or when they
initially enquired about the trial. However, no differences in consent rates were
distinguished by method of recruitment by the time potential candidates were
assessed for trial eligibility. Despite lower consent rates, higher numbers of study
participants were recruited by methods that approached large numbers of
potential candidates. Other methods such as framing of recruitment material, the
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offer of monetary incentives, the use of an interactive computer programme and
mailing of recruitment material accompanied by a letter signed by the trial
investigator were also effective. Stated recruitment costs ranged from US$0 to
$1108 per participant, with mailing being the most cost-effective method and
community approach the least effective overall.
7.2.2 Paediatricians’ attitudes to children’s participation in randomised
controlled trials (focus group research)
Paediatricians believed parents balanced perceived gains and risks when
deciding about trial participation. They thought the child’s condition, parents’
health beliefs and personal attributes, the doctors’ beliefs and relationship with
the investigators influenced parents’ attitudes. Perceived gains included
professional benefits for paediatricians, improved patient care, convenience for
the families and themselves and scientific advancement. Perceived risks
included inconvenience, inadequate resources and potential harms to the patient
and doctor-patient relationship. Paediatricians with previous research experience
were most knowledgeable about RCTs and perceived greatest gains from trial
participation. Paediatricians’ personal treatment preferences hindered trial
support.
7.2.3 Australian paediatricians’ and adult physicians’ attitudes to randomised
controlled trials (survey)
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Australian paediatricians and adult physicians are very similar in their treatment
philosophies, and are clinician-oriented rather than research-oriented in their
attitudes, with primary allegiance to their patients and preference for selecting
treatment rather than referring for trial participation in the face of treatment
uncertainty.  Professional activities are clinically focused, with limited time
assigned for research.  Australian doctors perceive little reward for trial
participation. Predictors of favourable attitudes to trial participation are time
allocation for research, past history of enrolling patients to trials and younger
age.
7.2.4 Parents’ attitudes to children’s participation in randomised controlled trials
(focus group research)
Findings from this study confirmed some of the paediatricians’ insights regarding
parents’ decision making for trial participation. Parents balance risks and benefits
when deciding about trial participation for their child. Perceived benefits for
parents include the offer of hope, better care of their child, the opportunity to
access new treatments, healthcare professionals and health information, meeting
others in similar circumstances and helping others. Perceived risks include
potential side effects, being randomised to ineffective treatments and the
inconvenience of participation. The decision for trial participation is also
influenced by parental factors (parents’ knowledge, beliefs and emotional
response), child factors (the child’s health status and preference about
participation), trial factors (the use of placebos and uncertainties of participation)
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and doctor factors (doctor’s recommendations and communication of trial
information).
7.3 Limitations
7.3.1 Recruitment strategies used to encourage participation in randomised
controlled trials (systematic review)
Many challenges were encountered when conducting the systematic review.
Because of the small number of RCTs assessing strategies for recruiting
participants into RCTs, the inclusion criteria was expanded to include
observational studies, which were more difficult to assess. Difficulties
encountered in systematically reviewing observational studies include a lack of
consensus about how this should be conducted, including what items should be
measured to assess study quality, as well as methodological issues of combining
results of non-random studies.
Due to the broad nature of the terms used in the search strategy (such as
recruitment, enrolment, accrual, and consent), a very large number (>8600) of
titles and abstracts had to be reviewed which was very time consuming. The
chance of missing an eligible study was minimised by including any studies found
by either researcher reviewing the titles and abstracts.
Although it is important to attempt to identify unreported trials by searching the
“grey literature” as this reduces publication bias, it was difficult to know how
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many unpublished studies exist and to know how to best access them. A limited
attempt at doing this was made. There are currently no guidelines on how this
should be done.
The poor quality of most of the included studies limited the generalisability of the
results. Potential bias in the studies includes selection bias, bias in how exposure
and outcomes were measured as well as confounding and loss to follow up. The
inclusion of non-random studies increased the potential for selection bias.
Measurement of exposure can be difficult for some recruitment methods such as
media, and may differ between studies (e.g. for community presentation, some
studies count the number of people attending the meeting, while others
approximate the number). Bias in measuring outcomes includes the definition of
consent (some studies measure intention to enrol and others measure actual
enrolment). As the definition of consent rate varied between studies,
standardisation of the measurement was attempted by describing the three types
of consent rates – “exposed”, “responder” and “assessed”. Although the
“exposed consent rate” most closely reflects the effectiveness of the recruitment
method, very few studies described this. “Response” may mean different things
in different studies or for different recruitment methods (e.g. someone
“responding” and picking up a pamphlet may be compared with a potential
participant’s detailed discussion with a health care provider about trial
participation). The assessment of recruitment cost for the methods of recruitment
was not measured in the same way in each study (e.g. infrastructure and other
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costs were not consistently included, resulting in the reported cost of recruitment
by health care provide referrals to range from $0 to $868 per participant
enrolled).
The heterogeneity of the recruitment methods created a problem for comparing
studies, as some studies compared different categories of methods, some
variations within one category, and some both.  Studies were divided into those
evaluating different categories of recruitment methods and those evaluating
variations within the same category in an attempt to summarise the data. This
resulted in the loss of data for variations within categories for studies that
compared different categories of recruitment methods. Because of the
heterogeneity between studies, it was inappropriate to combine results to
produce a single estimate of effect.
The definition of  “effectiveness” was problematic, as it should incorporate
consent rates as well as the proportion recruited by each method.  For example,
a method such as health care provider referral may have 100% consent rate, but
if only 2% of the total study population was recruited by that method, it would not
be an effective method. In studies evaluating variations of strategies within one
category of recruitment method, an attempt was made to combine “exposure
consent rates” and proportion enrolled by the method. However, this was difficult
to measure in the studies comparing different categories, as there were very few
studies where “exposure consent rates” could be derived. In measuring
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effectiveness, the time it takes to recruit by the method is also important, as the
success of trials also depends on timely recruitment. For example, health care
provider referrals may have a high consent rate and low cost, but if it takes years
to recruit an adequate number of study participants, this is not an effective
method. In the systematic review, no attempt was taken to measure time taken
for recruitment.
7.3.2 Paediatricians’ attitudes to children’s participation in randomised
controlled trials (focus group research)
The use of qualitative methods has the limitation that response size cannot be
measured. The participants of the focus group discussion for paediatricians were
recruited from the Children’s Hospital at Westmead, a tertiary referral teaching
hospital with a strong research focus located within a large city in Australia. Their
responses therefore cannot be generalised to paediatricians outside of that
setting. It is postulated, however, that paediatricians outside of that setting are
likely to be less research focused, and the results of this study therefore highlight
the plight of paediatric clinical research.
Although purposive sampling was employed to ensure that all groups with unique
views were presented, the non-attendance by some who were invited to
participate may bias the results. Also, participant responses may be influenced
by the presence of the researcher who was known to them, despite the attempt
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to address this issue by employing a professional facilitator not known to the
participants to conduct the groups.
7.3.3 Australian paediatricians’ and adult physicians’ attitudes to randomised
controlled trials (survey)
The relatively low response rate of 60% for the doctors’ questionnaire, despite
attempts at encouraging survey return by contacting non-responders at least
twice to minimise response bias, limits generalisability of the results, as non-
responders may answer the questionnaire differently to responders. As
participants were randomly selected from the Royal Australasian College of
Physicians register, a number were not in active clinical practice, for which the
questionnaire is more relevant. Ideally, non-clinicians should have been excluded
prior to random selection. This may have increased the participation rate.
The use of the “Physician Oriented Profile” posed some problems in the study
context as the questionnaire was initially written for cancer specialists. Some
questions that were not relevant to the non-oncology context had to be excluded
or altered. Australian doctors also disliked answering binary-option questions,
preferring an answer “in between”. Although the rationale for using binary-option
questions (to ensure that the final score has good predictive value and can be
compared with UK and US data) was explained, many chose either to not answer
some questions or else to write an alternative answer instead of choosing
between available options, while others co-operated. As the mean “POP” score is
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derived from the total score divided by the number of questions answered,
unanswered questions or questions which did not match one of the options were
excluded. This had the potential to bias the outcome (for example, some doctors
may not feel comfortable with answering questions that reveal their “clinician
orientation” or their “researcher orientation”).
Comparison with UK and US data was difficult to interpret because this study
was conducted some 5-15 years later and differences in response may partly be
due to changes over time. Another factor may be different attitudes to RCTs
among different specialties, as the UK and US studies were with cancer
specialists, and this questionnaire was applied to physicians from a broad range
of subspecialties. Comparison with the subgroup of Australian
haematologists/oncologists was difficult to interpret due to the small number
(twelve) of Australian haematologists/oncologists who participated.
7.3.4 Parents’ attitudes to children’s participation in randomised controlled trials
(focus group research)
One of the difficulties encountered with parents’ focus groups was the poor
attendance of some groups of parents. For example, of 46 parents approached
for focus group participation, 17 agreed to participate, but none actually attended
the focus group. Due to the poor focus group attendance, other suitable parents
were approached and interviewed in the ward individually or in pairs. Although
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the same prompts were used for the interviews, the group dynamics was lacking
which may have influenced responses.
Although purposive sampling was attempted by inviting parents from five different
settings (parents from a local primary school, from the hospital oncology unit,
renal treatment centre, inpatient wards and research groups), and relevant
paediatricians and researchers from the hospital were requested to identify
parents who may provide a range of views to participate in the focus groups,
most parents attending the groups were in favour of paediatric research. It was
not known if there was any selection bias, although it is quite likely, as those less
favourable towards paediatric trials were less likely to participate.
The choice of a medical researcher to facilitate the parents’ focus groups may
not have been ideal, as parents are more likely to respond in a way which they
think may please the researcher.
7.4 Implications of findings
The results of the systematic review have implications for researchers designing
trials. It is important to consider consent rates as well as proportions enrolled by
a method when considering what strategies to employ. The use of health care
professional referral is associated with a higher consent rate, but reliance on this
method alone may limit the exposure of potential participants. Other methods
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where larger numbers of potential participants are exposed to trial information
such as mailing may be more cost effective.
The effectiveness of framing trial information in such a way as to emphasise the
uncertainty of current best treatment and the need to improve early diagnosis
and management is very exciting and has implications for researchers, as this
strategy attracts little additional cost and can be incorporated into other methods
of recruitment. Consideration should be given to the wording of recruitment
information and care must be taken to ensure the method is ethically sound.
When recruiting children for trial participation, researchers should consider the
needs and concerns of parents and paediatricians. Suggestions include
improving communication between researchers, paediatricians and parents and
improving the gains-hazard balance (by increasing incentives while decreasing
inconveniences).
This study also has implications for major research institutions that are seeking
solutions to the crisis in clinical research in health care. Major reforms in the
health care system are needed to address the low priority placed on clinical
research by clinicians, such as restructuring clinical research in a setting which is
primarily clinically orientated.
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7.5 Future research
This thesis suggests a number of possible avenues for future research. The
results of the systematic review suggest that there is still a need to assess
promising recruitment methods. Uncertainty still remains about the effectiveness
of different recruitment methods, which could be tested by a randomised-
controlled trial. The effectiveness of the interactive computer programme
compared with passively listening to a tape recording of trial material has
potential for application where Internet access is readily available. Although
Internet recruitment for RCTs is known to occur, this method has never been
assessed in a trial setting.
The importance of high consent rates and greater exposure of potential
participants to trial information should be incorporated by researchers in the
design of effective recruitment strategies. The one study assessing different
variations of mailing methods found higher consent rates among people who
received recruitment material accompanied by a letter from the trial investigator,
even though the letter was identical to the one sent by the director of the health
insurance company (141). What is the reason for this response? Do people feel a
trial investigator is more personal than the director of an insurance company?
How do people identify who they trust? These basic questions can unlock an
understanding of the decision making process which can be helpful both to
patients and doctors.
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Although recruitment data are readily accessible for many trials, these data are
not often collected. With the introduction of a centralised trials register in the
future, this information should be collected, pooled and analysed to improve our
understanding of recruitment. It is therefore important to define stages of
recruitment so accurate measurements can be made and compared.
The conclusions from the two studies of paediatricians’ attitudes to RCTs
suggest personal treatment preferences hinder trial support whereas allocated
research time and trial participation by doctors enhance their support. The
mandatory research projects of the Australasian College of Physicians for
FRACP accreditation are designed to foster research interest. It is currently
unclear whether this component has been effective, but should be assessed.
The findings from the parents’ focus groups challenge researchers to address the
issue of parents’ emotional response to their child’s participation in a trial and to
develop ways of helping parents deal rationally with their reactions (which they
acknowledge defy reason). The acknowledgement by parents that how they are
approached by doctors and how the trial was explained influenced their decision
for trial participation, and the study from the systematic review which
demonstrated that informing doctors of the patient’s preferences and views about
trials improved recruitment suggest that the training of doctors in information
giving, particularly for trial participation, is helpful and appreciated by patients.
172
The challenges encountered by  the difficult recruitment for the parents’ focus
group, and the complete lack of data on this subject has great potential for further
study, as qualitative research is increasingly being embraced by the scientific
community who has recognised the wealth and depth of information that can be
attained using these techniques.
What are children’s attitudes to RCTs? Although parents’ and paediatricians’
responses were explored in this study, it is important to ask the children
themselves.
7.6 Conclusion
The randomised-controlled trial provides a scientifically valid and ethically sound
technique for assessing the effects of healthcare interventions. However, even
the best designed trials depend on recruitment of adequate numbers of study
participants for success. The inclusion of children in trials is both necessary and
desirable, but is often limited by inadequate recruitment. This thesis
systematically reviews previous strategies used for recruiting study participants
into RCTs, explores recruitment issues from the perspective of paediatricians
and parents (the key gatekeepers for children’s RCTs participation) and identifies
aspects of the recruitment process that could be modified to improve trial
participation for children.
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Appendix A: Data extraction form for the systematic review
Data Extraction Form:  Reviewer: ………………………
Study details:
 First author  
 Year  
 Country of publication  
 Publication type  Journal / Abstract / other (specify)
 Name of Journal  
 
Study Eligibility/Characteristics
Inclusion Criteria for Systematic Review Study
Type of study RCT, QRCT, CS, CCS (P), CCS (H), CSA, BAS,
ES, DS
yes          no          unclear
Setting of study
(Describe study, incorporating:
Participants
Source – where pt from
Setting of RCT - what is RCT
about)
Types of intervention  
 
 
 
 Types of outcome measures
mentioned
· Accrual rate
· Efficiency
· Cost per participant
· Other
Methods: Trial Quality (only for RCT/QRCT)
Method of randomisation
Allocation concealment Clearly yes, unclear, no
Other method comments
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Participants
Total Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
#f participants
Total exposed
Responded
1st screened
Eligible
Enrolled
Randomised
Ineligible
Refused
Lost to follow
up
Efficiency of
each method
(% enrolled)
Cost
Intervention/ Outcome measures (when appropriate: Mean+SD)
Confounders comparable between
groups and adjusted for?
Outcome measured in the same
way for groups? Blinding?
Outcome measured in a valid way?
Adverse effects mentioned
Notes
· Investigators contacted for
more information
· Raw data: available/
requested/obtained
Notes
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Appendix C: Prompts for paediatricians’ focus group discussions
Trials – how does it affect the doctor?
· What do you enjoy about participating in trials?
· What do you see as the advantages of participating in trials? (to you, your
patients and the community)
· What do you dislike about participating in trials?
· What do you find difficult about participating in trials?
· What is the difference between trials you have enjoyed participating in and
those that you haven’t?”  (research question, trial factors, investigator
factors)
· Are there any trials you would not participate in and why (specifics)?
Perceptions of patient factors
· Do you think some patients/parents are more likely to participate than
others? If so…
· Do you think there are some patients/parents who should not be asked to
participate in a RCT?
· What do you think would improve the conduct of RCTs?
186
Appendix D: Demographic questionnaire for the paediatricians’ focus
groups
“Recruitment of children in randomised controlled trials”
Focus group for paediatricians
The information on this sheet is confidential. It will be used to define the demographics of the
participants attending this focus group.
Please tick appropriate boxes
1. What is your position?  VMO - general paediatrician
 AMO - general paediatrician (Staff Specialist)
 AMO - subspecialist (Staff Specialist)
 Fellow
 Registrar
2. What is your age? 
3. What is your sex?  male  female
4. What is your country of origin? _____________________________
(i.e. with what culture do you identify?)
5. Do you have children?  no
 yes
If yes, do any of them fall within the following age brackets?
 0-5  6-12  13-18  19+
6. Do you have grandchildren?  no
 yes
If yes, do any of them fall within the following age brackets?
 0-5  6-12  13-18  19+
7. How many years have you worked as a doctor?  years
8. Regarding your previous experience with children participating in
randomised controlled trials (RCTs):
 I have referred one or more of my patients to a RCT in the
past
 I have participated in conducting a RCT in the past
 I have referred one or more of my patients to a RCT in the last
year
 I have participated in conducting a RCT in the last year
Thank you for completing this survey
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Appendix E: Physician and paediatrician’s questionnaire
“Attitudes of physicians and paediatricians to randomised controlled trials”
The information on this sheet is confidential.
Please tick appropriate boxes
Some of the questions in this questionnaire force you to choose between only two options
and you may feel your true response falls somewhere in between. We acknowledge that such
choices can be hard; however, the questionnaire was designed this way to ensure that the
final score has good predictive value. The scale has been completed previously in Europe
and America by thousands of clinicians, and our capacity to compare data cross-culturally
would be lost if we changed the questionnaire. Please choose the answer that most closely
matches your true response.
1. Age  
2. Sex: Male Female
3. Specialty: Adult Physician Paediatrician 
4. Subspecialty: No Yes (please
specify)__________________
5. (a) Primary setting for clinical practice:
Private practice Teaching hospital Non teaching hospital
Other (please specify)________________________________________
(b) Location of practice: 
Urban Rural
6. Appointment:
VMO Staff Specialist Academic 
Other (please specify)________________________________________
7. How many patients do you see each week?
 0 1-20 21-50 51-100 >100
8. Have you ever enrolled patients in randomised controlled trials?
Yes  No
9. How many of your patients participated in a randomised controlled trial in
the last year?
 0 1-10 >10
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10. How much time do you devote to research?
None <30% research 30-50% research 
50-70% research >70% research
11.  How many articles have you published in the last year?
 0 1 2 3 >3
12.  Although many doctors are expected to perform both tasks, as a doctor
my primary commitment is to:
 future generations of patients (society)
 present patients (individual)
13.  When there is controversy in the literature as to which treatment is best:
 I enter the patient in a clinical trial if one exists
 I personally select a treatment for the patient
14.  If I had to choose, I would say my primary task is:
 caring for individual patients
 contributing to scientific knowledge
15.  In my hospital, doctors are given more reward for:
 clinical skills with patients
 contributing to scientific knowledge
16.  If written informed consent was not required, I would approach more
patients to enter clinical trials
 true
 makes no difference
17.  When making critical and controversial decisions, I usually:
 seek major input from my patients
 do not seek major input from my patients
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18.  Ideally I would like to refer or enter the following proportion of my
potentially eligible patients into randomised clinical trials:
 none  some  half  most  all
19. The time I devote to publications, lectures and research commitments,
compared to clinical work, is relatively:
 totally devoted to clinical work
 mainly devoted to clinical work
 devoted equally to clinical work and research
 mainly devoted to research
 totally devoted to research
20.  My income is:
 dependent on my research activities
 not dependent on my research activities
21.  I would like to assess how successful I was as a physician by:
 my research contribution
 how I helped individual patients
22.  I would rather be somewhat:
 too involved with my patients
 too detached from my patients
23.  If a patient refuses to participate in a randomised clinical trial, I would:
 treat the patient off the study
 refer the patient to another doctor
24.  I would rather be known for:
 my interpersonal skills with patients
 my research accomplishments
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25.  Overall I feel the quality of patient care:
 increases when a patient is in a clinical trial
 decreases when a patient is in a clinical trial
 does not change when a patient is in a clinical trial
26.  When published data and my clinical judgement conflict, I am more likely
to rely on:
 my clinical experience
 published data
27.  Randomised clinical trials restrict my ability to individualise patient care
 true
 makes no difference
28.  In my hospital the pressure to participate in a randomised clinical trial is
relatively:
 low
 high
29.  The need for detailed monitoring of my management of trial patients by
trial staff deters me from participating in randomised clinical trials:
 no
 yes
30. The increased paperwork involved in treating patients on trials deters me
from participating in randomised clinical trials:
 no
 yes
31.  When a potentially eligible patient chooses not to enrol on a trial that I
have suggested, I:
 often feel disappointed
 seldom feel disappointed
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32.  Frequent publications are important to my career advancement:
 agree
 disagree
33.  When a protocol includes a treatment that is more aggressive than I
would usually give to similar non-trial patients:
 I am often reluctant to participate
 it makes no difference
34. When a protocol includes a treatment that is less aggressive than I would
usually give to similar non-trial patients:
 I am often reluctant to participate
 it makes no difference
35.  I am reluctant to participate in a trial that may randomise the patient to a
‘no treatment’ group:
 agree
 disagree
36.  The opinions of the patient’s usual doctor regarding randomised clinical
trials affects my decision to approach an eligible patient:
 true
 false
37.  The thought of having to spell out all the details of a trial to eligible
patients discourages me from approaching them to participate:
 true
 false
38.  A major reason for my participation in randomised clinical trials is that it
financially benefits my institution or department:
 agree
 disagree
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39.  Overall, involvement in randomised clinical trials:
 enhances my reputation
 does not enhance my reputation
40.  When I am personally uncertain as to which treatment is best, I am likely
to:
 enter the patient in a randomised clinical trial if I am aware one
exists
 personally select a treatment
41.  If research activities were to enhance my income, I would enter more
patients in randomised clinical trials:
 agree
 disagree
42.  I am more likely to attend a conference that focuses on:
 clinical issues
 research issues
43.   I think the patient’s right to select treatment options is always more
important than the advancement of scientific knowledge:
 true
 false
44.  When I participate in a randomised clinical trial, it is more likely that I:
 increase my patient population
 lose patients I might otherwise keep
 it makes no difference to my patient population
Thank you for completing this survey. Your help is greatly appreciated.
Comments:
                                                       
  Version 4, 22-Apr-2002
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Appendix F: Prompts for parents’ focus group on “Attitudes to
children’s participation in randomised controlled trials”
General attitudes to clinical research
· What do you think about medical research that involves people?
· What do you think about research involving children?
· Should parents be informed about trials being conducted, which may be
relevant to their child’s condition?
· Should doctors decide whether to tell parents about trials that may be
relevant to their child’s condition?
· How much should children be involved in the decision about participating
in a trial?
Knowledge of research
· Do you know about the different types of research? (Questionnaires,
RCTs)
Randomised controlled trials
· What do you know about randomised controlled trials?
(An explanation of randomised controlled trial is given by facilitator:
A randomised controlled trial is a special study which can find out what is the
best treatment, when it is not clear which treatment is best. When a
randomised controlled trial is conducted, nobody, not even the doctors or
scientists, know which is the better treatment. What is known is that all of the
treatments used are effective in treating the disease.  Preliminary studies
have also been done to prove that all the treatments are safe and any new
treatments are not going to be worse than the standard treatments. If it was
not safe, the trial would not be conducted. There are usually two treatments
being compared, and the treatment each child receives is decided by chance.
It is necessary to decide the treatment by chance to make sure that at the
beginning of the study, both groups of children are very similar. Therefore we
know that any differences at the end of the study will be due to the treatment
alone. For example, if someone, like the doctor, decided which treatment
each child would have, he or she might give some children (say the older
children) one treatment, and the younger children the other – then differences
at the end might be due to age, rather than the treatment itself.
· How do you feel about the child’s treatment being allocated by chance?
There are some trials that compare 2 medications. For example, there are
asthma trials that compare Medicine A with Medicine B, and each child will
receive either Medicine A or Medicine B
· What questions might you have if your child was invited a trial like this?
Sometimes, randomised controlled trials involve the use of a placebo, which is
a nonactive medication. It is used when testing whether using a particular
treatment is better than not using anything. Each child will receive either the
treatment being tested or the placebo.
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· How would it be different if your child was invited to an asthma trial, which
compared Medicine A with a placebo (compared with a trial that compared
2 treatments)?
In the treatment of childhood cancers, one combination of drugs is often
compared with another combination.
· What questions might you have if your child was invited to participate in
cancer trials, which compared one combination of drugs with another?
Motivators and Barriers
· What do you think are some of the benefits for children being involved in a
randomised controlled trial?
· What do you think are some of the problems with children being involved
in a randomised controlled trial?
· Why do you think some parents might be reluctant or keen for their
children to be involved in a randomised controlled trial?
· Would you feel differently if it were you rather than your child who was
asked to participate in a randomised controlled trial? Why?
Future
· How can we help parents to understand more about randomised controlled
trials?
· From the parents and patients’ point of view, what do you think are some
of the things that researchers need to think of when they design research?
· How can we improve research involving children in the future?
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Appendix G: Demographic questionnaire for parents’ focus groups
“Attitudes to children’s participation in randomised controlled trials”
Focus group for Parents
The information on this sheet is confidential. It will be used to define the participants attending
this focus group.
Please tick appropriate boxes
1. Who are you in relationship to the child?
 Father  Step-Father  Male guardian
 Mother  Step-Mother  Female guardian
2. How old are you?  
3. How many children are currently living in your household?  
4. What is the postcode of your place of residence?    
5. What is your level of education?
 School Certificate (up to year 10)
 High School Certificate (year 12)
 Tertiary
6. What is your country of origin? _____________________________
(i.e. with what culture do you identify?)
7. Have you or any of your children ever participated in a randomised
controlled trial in the past? 
 yes  no
Thank you for completing this survey. Your help is greatly appreciated.
…………………………………………………………………………………………………………
If you would like feedback about this research, please fill in your name and address below.
 Yes, I would like feedback about this research.
Name: ________________________________________________________
Address: ______________________________________________________
______________________________________________________________
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